

Imagine better health.®

# **Quarterly Report**

As of December 31, 2018, and for the three and six months ended December 31, 2018 and 2017

**Information Concerning Catholic Health Initiatives** 

# Table of Contents

PART I:	OVERVIEW1
PART II:	Q2 & FYTD 2019 HIGHLIGHTS & SUMMARY2
PART III:	STRATEGIC AFFILIATIONS & DIVESTITURES
PART IV:	SELECTED FINANCIAL DATA
1. Crit	cical Accounting Policies8
PART V:	MANAGEMENT'S DISCUSSION & ANALYSIS
1. Sur	nmary of Operating Results for the three months ended December 31, 2018 and 2017 12
<b>2.</b> Sur	nmary of Operating Results for the six months ended December 31, 2018 and 2017
3. Sur	nmary of Balance Sheets as of December 31, 2018 and June 30, 2018
4. Cer	tain Contractual Obligations
5. Liq	uidity and Capital Resources
6. Liq	uidity Report
PART VI:	LEGAL PROCEEDINGS
APPENDI	X A: CATHOLIC HEALTH INITIATIVES CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF DECEMBER 31, 2018 AND FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2018 AND 2017

This Quarterly Report should be reviewed in conjunction with the information contained in the Annual Report dated September 28, 2018 (the "Annual Report"), which can be found at <a href="http://emma.msrb.org">http://emma.msrb.org</a>.

Certain of the discussions included in this Quarterly Report may include forward-looking statements. Such statements are generally identifiable by the terminology used such as "believes," "anticipates," "intends," "scheduled," "plans," "expects," "estimates," "budget" or other similar words. Such forward-looking statements are primarily included in PARTS II, III, IV and V. These statements reflect the current views of management with respect to future events based on certain assumptions, and are subject to risks and uncertainties. Catholic Health Initiatives, a Colorado non-profit corporation (the "Corporation"), undertakes no obligation to publicly update or review any forward-looking statement as a result of new information or future events.

References to "CHI" in this Quarterly Report are to the Corporation and all of the affiliates and subsidiaries ("Participants") consolidated with it pursuant to U.S. generally accepted accounting principles ("GAAP"). References to the Corporation are references only to the parent corporation, and should not be read to include any of the Participants.

Unless otherwise noted, all financial information in this Quarterly Report, for the three and six months ended December 31, 2018 and 2017, refers to continuing operations only.

# PART I: OVERVIEW

Catholic Health Initiatives ("CHI") is a group of non-profit and for profit organizations that comprise one of the nation's largest Catholic health care systems, serving more than four million people each year through operations and facilities that span the continuum of care, including acute care hospitals; physician practices; long-term care facilities; assisted-living and residential-living facilities; community-based health services; home care; research and development; medical and nursing education; reference laboratory services; virtual health services; managed care programs; and clinically integrated networks. Today, CHI has operations in 18 states, with a service area that covers approximately 54 million people, or nearly 17% of the U.S. population.

At December 31, 2018, CHI was comprised of ten regions that are operated as integrated health systems including several joint operating agreements ("JOAs"), joint operating companies ("JOCs") or joint ventures. The geographic diversity and total operating revenues by region for the fiscal year ended June 30, 2018 are depicted in the accompanying map.



# PART II: Q2 & FYTD 2019 HIGHLIGHTS & SUMMARY

CHI's operating EBIDA declined \$51.3 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017. Total revenues increased \$15.3 million or 0.4% on a consolidated basis, and increased \$113.2 million or 3.0% on a same store basis. Same store net patient services revenue per adjusted admission remained strong and increased \$505 (per adjusted admission) or 3.7% for the three months ended December 31, 2018, compared to three months ended December 31, 2017, due to regional contract rate increases and other revenue cycle improvements, increased provider fee revenue as well as increases in overall acuity. Same store operating expenses increased 4.5% across most expense categories.

Total restructuring, impairment and other losses increased \$4.3 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, due primarily to affiliation related costs (as further outlined on page 18).

Non-operating income for the three months ended December 31, 2018 declined \$580.0 million compared to the three months ended December 31, 2017, due primarily to negative investment returns in the capital markets.

The following table reflects summary income statement indicators and the year-over-year change for the three months ended December 31, 2018:

			ey Operating Indicators for Continuing Operations Three Months Ended December 31,				
(\$ in millions)	Unaudited	2018	2017	Increase (Decrease)			
Operating EBIDA		\$230.5	\$281.8	\$(51.3)			
Operating EBIDA margin		6.0%	7.4%				
Loss from operations		\$(57.2)	\$(1.5)	\$(55.7)			
Operating loss margin		(1.5)%	(0.0)%				
Net (loss) income <sup>1</sup>		\$(420.0)	\$215.6	\$(635.6)			
Net (loss) income margin		(12.1)%	5.3%				

<sup>&</sup>lt;sup>1</sup> Excess (deficit) of revenues over expenses.

CHI's operating EBIDA declined \$49.0 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, adjusting for transactional gains and other items (as further outlined on page 18). Total revenues increased \$47.9 million or 0.6% on a consolidated basis and increased \$234.1 million or 3.2% on a same store basis for the six months ended December 31, 2018, compared to the six months ended December 31, 2017. Total net patient services revenues increased \$233.3 million or 3.4% and net patient services revenues per adjusted admission increased \$477 or 3.5% on a same store basis for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due to increased acuity, provider fee revenue and contract rate increases across many markets. Although revenue per adjusted admission growth was positive, the increase did not offset the overall expense increases across the system.

Volumes on an adjusted admission and same store basis declined slightly at 0.2% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017. Total same store labor costs as a percentage of net patient services revenues decreased slightly to 50.0% for the six months ended December 31, 2018, compared to 50.3% for the six months ended December 31, 2017. Total same store supplies as a percentage of net patient services revenues increased slightly to 17.4% for the six months ended December 31, 2018 compared to 17.1% for the six months ended December 31, 2017.

Total restructuring, impairment and other losses increased \$11.3 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017 due primarily to affiliation related costs (as further outlined on page 25).

Non-operating income for the six months ended December 31, 2018 declined \$644.8 million compared to the six months ended December 31, 2017, due primarily to negative investment returns in the capital markets.

The following table reflects summary income statement indicators and the year-over-year change for the six months ended December 31, 2018:

		Key Operating Indicators for Continuing Operation Six Months Ended December 31,				
(\$ in millions)	Unaudited	2018	2017	Increase (Decrease)		
Operating EBIDA		\$445.3	\$504.6	\$(59.3)		
Operating EBIDA margin		5.9%	6.7%			
Loss from operations		\$(130.7)	\$(79.4)	\$(51.3)		
Operating loss margin		(1.7)%	(1.1)%			
Net (loss) income <sup>1</sup>		\$(345.1)	\$351.0	\$(696.1)		
Net (loss) income margin		(4.7)%	4.4%			

<sup>&</sup>lt;sup>1</sup> Excess (deficit) of revenues over expenses.

# PART III: STRATEGIC AFFILIATIONS & DIVESTITURES

CHI actively engages in ongoing monitoring and evaluation of potential facility expansion, relationships with academic health center partners, mergers, acquisitions, divestitures, and affiliation opportunities consistent with its strategic goal of creating, maintaining and/or strengthening its clinically integrated networks ("CINs") in key existing markets and, in certain cases, new markets. CHI's strategic vision is supported by focused system growth in both existing and new markets, as evidenced by recent acquisition activity and strategic divestitures, and realignments, certain of which are described below.

# A. Pending and Completed Affiliations/Acquisitions/Transactions

**CommonSpirit Health**. Effective February 1, 2019, the Corporation and Dignity Health, a California not-for-profit public benefit corporation, aligned their respective ministries as a single, Catholic, not-for-profit health system known as CommonSpirit Health (the "Transaction"). The new organization has established its corporate headquarters in Chicago. Local facilities will continue operating under their current names.

Prior to the Transaction, the Corporation and Dignity Health were each the direct or indirect parent corporation of separate groups of not-for-profit and for-profit entities that comprised the "Legacy CHI System" and the "Legacy Dignity Health System", respectively, and together the "Legacy Systems." Effective February 1, 2019, the Corporation changed its name to "CommonSpirit Health." References to the "Corporation" in this Quarterly Report are to the Colorado not-for-profit corporation formerly known as Catholic Health Initiatives and now known as CommonSpirit Health. References to "CommonSpirit Health" herein shall mean and refer to the combined Legacy Systems, including their respective affiliates and subsidiaries.

Dignity Health owns and operates 41 acute care hospitals in California, Arizona and Nevada and 400+ ancillary care sites across 22 states. As of and for the fiscal year ended June 30, 2018, Dignity Health reported approximately \$18.1 billion of total assets, \$8.4 billion of net assets and \$14.2 billion in total operating revenue.

CommonSpirit Health is now led by the Office of the CEO, with both Kevin E. Lofton, formerly the CEO of the Legacy CHI System and Lloyd Dean, formerly the President and CEO of the Legacy Dignity Health System, serving as CEOs, each with specific and independent responsibilities and decision-making authority. Together, the CEOs jointly

oversee strategy and integration planning. Mr. Lofton has authority for advocacy; compliance; digital; information technology; international business; legal services; philanthropy; mission; sponsorship and governance; and system partnerships. Mr. Dean has authority for all operations and all clinical, financial, and human resources of the new ministry. They will work side by side with executive leadership to plan a successful integration of CommonSpirit Health.

The executive leadership team members of CommonSpirit Health have been appointed and became effective February 1, 2019. Marvin R. O'Quinn, formerly Senior Executive Vice President and Chief Operating Officer of the Legacy Dignity Health System, is President and Chief Operating Officer, Daniel J. Morissette, formerly Senior Executive Vice President and Chief Financial Officer of the Legacy Dignity Health System, is Senior Executive Vice President, Corporate Affairs and Chief Legal Officer of the Legacy CHI System, is Senior Executive Vice President and Chief Legal Officer.

The governing board for CommonSpirit Health, the Board of Stewardship Trustees, has been selected and became effective February 1, 2019. The new Board of Stewardship Trustees includes six members from each Legacy System, the two CEOs and an additional member to be determined at a later date.

Notwithstanding the consolidation of the financial statements as of February 1, 2019, the indebtedness and other obligations of the respective Legacy Systems (the "Existing Debt") remains the separate legal obligations of the respective Legacy System, until such Existing Debt is restructured and consolidated into a single credit (the "Debt Consolidation"). The Existing Debt of the Legacy CHI System, the majority of which is evidenced by Obligations issued by the Corporation under its Capital Obligation Document, has not been modified, and the Corporation remains as the obligor on that Existing Debt. The Existing Debt of the Legacy Dignity Health System, the majority of which is secured by and subject to the provisions of its Master Trust Indenture, has not been modified, and the Members of the Obligated Group established under the Dignity Health Master Trust Indenture remain as the obligors on that Existing Debt.

Any Debt Consolidation will be dependent upon the terms and conditions of each Legacy System's Existing Debt and other agreements, and then-existing financial, credit, and capital market conditions. There can be no assurance that any Existing Debt will be refinanced, and if such Existing Debt is refinanced, the timing thereof.

**Civica Rx**. In September 2018, CHI joined with six major, nationally recognized health systems to form Civica Rx, a not-for-profit generic drug company that will help patients by addressing shortages and high prices of life saving medications. Once manufacturing approval is obtained from the FDA, Civica Rx will either directly manufacture generic drugs or sub-contract manufacturing with reputable organizations. Its initial goal is to stabilize the supply of essential generic medications administered in hospitals, since many of the medications are in chronic short supply. Civica Rx expects to have its first products on the market as early as 2019.

# B. Pending and Completed Divestitures and /or Restructurings

**KentuckyOne Health.** In November 2012, KentuckyOne entered into a Joint Operating Agreement ("Kentucky JOA") and an Academic Affiliation Agreement ("AAA") (collectively "Agreements") with University of Louisville ("U of L"), University Medical Center, Inc. ("UMC"), which owns the University of Louisville Hospital, and other parties.

On December 17, 2016, KentuckyOne, UMC and U of L agreed to restructure the Kentucky JOA. The operations, management and control of the University of Louisville Hospital was transferred back to UMC effective July 1, 2017. The AAA was also restructured, and various transition services agreements were entered into in connection with the transfer of the University of Louisville Hospital to UMC.

In May 2017, the Corporation approved a plan to sell KentuckyOne's Louisville-area acute care operations, including certain operations and facilities owned by Jewish Hospital and St. Mary's Healthcare, Inc. ("JHSMH"). As a result, the Corporation will refocus the Kentucky region on a smaller community footprint, centered in central and eastern Kentucky.

Effective September 1, 2017, the Corporation assumed complete ownership of KentuckyOne when the Corporation purchased the non-controlling interest from the other partner for \$150 million in cash consideration.

In December 2017, the Corporation entered into a non-binding letter of intent to negotiate a definitive agreement for the sale of the KentuckyOne Louisville-area acute care operations, and as a result, CHI recorded impairment charges of \$272.0 million for the write-down of assets held for sale to their estimated fair value, less estimated costs to sell, as a result of this anticipated transaction. The impairment charge was recorded as a reduction in net assets through discontinued operations.

In June 2018, an updated non-binding letter of intent for the purchase of JHSMH was received and based upon the terms of that letter of intent, CHI recognized additional impairment charges of \$105.5 million in discontinued operations and \$11.8 million in continuing operations, to adjust the JHSMH property and equipment values to the lower of their carrying value or fair value net of cost to sell. CHI anticipates closing on a sale during fiscal year 2019.

Additionally, on December 29, 2018, the Corporation entered into a further non-binding proposal letter to negotiate a definitive agreement for the sale of the KentuckyOne Louisville-area acute care operations.

Effective June 28, 2018, the sale of the Southern Rehab Hospital to Vibra Healthcare was finalized. Effective July 1, 2018, Saint Joseph Martin was sold to Appalachian Regional Healthcare.

The following summarizes selected financial results of JHSMH included in the CHI consolidated statements of changes in net assets as discontinued operations:

	Six Months Ended December 31,				
(\$ in millions)	2018	2017	(Decrease)		
		Unaudited			
<b>ЈНЅМН</b>					
Operating revenues	\$364.4	\$368.4	\$(4.0)		
Operating EBIDA before restructuring, impairment and					
other losses	\$(29.0)	\$(34.7)	\$5.7		

The CHI consolidated balance sheets include JHSMH total assets held for sale of \$21.1 million and total liabilities held for sale of \$81.7 million at December 31, 2018.

**QualChoice.** In May 2016, the Corporation approved a plan to sell or otherwise dispose of certain assets, including stock of certain subsidiaries of QualChoice, a consolidated group of CHI direct and indirect subsidiaries, whose primary business is to develop, manage and market commercial and Medicare Advantage health insurance plans, as well as a wide range of products and administrative services. In June 2018, the Corporation entered into an asset purchase agreement for the sale of its Medicare Advantage health insurance operations in the State of Washington which was effective January 1, 2019. In December 2018, the Corporation also entered into an agreement for the sale of the QualChoice Health commercial operations in the State of Arkansas. The closing of the transactions contemplated under the agreement is pending regulatory approvals and is expected to receive regulatory approvals in the second half of fiscal year 2019.

The Corporation continues to actively manage QualChoice and has steadily improved operations since the announcement to sell or otherwise dispose of the operations, moving to a positive operating EBIDA before restructuring, impairment, and other losses of \$16.6 million for the six months ended December 31, 2018 from an operating EBIDA loss before restructuring, impairment and other losses of \$(8.2) million for the six months ended December 31, 2017.

The following summarizes the financial results of QualChoice reported in the CHI consolidated statements of changes in net assets:

		Six Months Ended December 31,	
(\$ in millions)	2018	2017	Increase
QualChoice		Unaudited	
Operating Revenues	\$284.9	\$268.6	\$16.3
Operating EBIDA before restructuring, impairment and other losses	\$16.6	\$(8.2)	\$24.8

The December 31, 2018 CHI consolidated balance sheets included QualChoice total assets held for sale of \$165.6 million and total liabilities held for sale of \$137.2 million.

# PART IV: SELECTED FINANCIAL DATA

The selected financial data that follows has been prepared by management, based on (i) CHI's unaudited interim financial statements as of December 31, 2018, and June 30, 2018, and for the three and six months ended December 31, 2018 and 2017. The unaudited financial statements include all adjustments, consisting of normal recurring accruals, which management of CHI considers necessary for a fair presentation of the combined financial position and results of operations for these periods. The unaudited interim financial statements for the three and six months ended December 31, 2018, are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2019.

The CHI consolidated financial information should be read in conjunction with the unaudited financial statements, related notes, and other financial information of CHI included in Appendix A of this Quarterly Report.

CHI participates in JOAs with hospital-based organizations in Colorado, Iowa and Ohio. The agreements generally provide for, among other things, joint management of the combined operations of the local facilities included in the JOAs through JOCs. CHI retains ownership of the assets, liabilities, equity, revenues and expenses of the CHI facilities that participate in the JOAs. Transfers of assets from facilities owned by the JOA participants are generally restricted under the terms of the agreements. The financial statements of the CHI facilities managed under all JOAs are included in the CHI consolidated financial statements.

As of December 31, 2018, CHI has investment interests of 65%, 50%, and 50% in JOCs based in Colorado, Iowa, and Ohio, respectively. CHI's interests in the JOCs are included in investments in unconsolidated organizations and totaled \$462.7 million and \$435.8 million at December 31, 2018 and June 30, 2018, respectively. CHI recognizes its investment in all JOCs under the equity method of accounting. The JOCs provide various levels of services to the related JOA sponsors, and operating expenses of the JOCs are allocated to each sponsoring organization.

Certain joint venture agreements do not result in the consolidation of the jointly owned entities with the Corporation. The results of those operations are reflected in the consolidated financial statements of CHI under the line item "Changes in equity of unconsolidated organizations".

6

# A. The following table provides condensed consolidated balance sheets as of December 31, 2018 and June 30, 2018.

Condensed Consolidated Balance Sheets	(\$ in thousands)	December 31, 2018 Unaudit	June 30, 2018		
Assets Current assets:		Gilduari	cu		
Cash and equivalents		\$ 871,505	\$ 510,456		
Net patient accounts receivable		2,164,406	2,121,582		
Assets held for sale		189,422	195,698		
Other current assets		925,941	764,272		
Total current assets		4,151,274	3,592,008		
Total carrent assets		4,131,274	3,332,000		
Investments and assets limited as to use:					
Internally designated investments		4,585,986	5,308,868		
Restricted investments		997,382	1,163,995		
Total investments and assets limited as to use		5,583,368	6,472,863		
Property and equipment, net		7,994,466	8,110,767		
Other assets		2,421,408	2,419,669		
Total assets		\$20,150,516	\$20,595,307		
Liabilities and net assets					
Current liabilities:					
Accounts payable and accrued expenses		\$2,305,557	\$2,181,021		
Liabilities held for sale		222,921	251,710		
Short-term and current portion of debt		2,094,374	2,184,106		
Total current liabilities		4,622,852	4,616,837		
Other liabilities		2,433,153	2,504,785		
Long-term debt		6,358,186	6,341,931		
Total liabilities		13,414,191	13,463,553		
Net assets:		, ·_ ·, - <b>_</b>	-,,		
Unrestricted		6,426,199	6,829,063		
Temporarily restricted		211,976	207,695		
Permanently restricted		98,150	94,996		
Total net assets		6,736,325	7,131,754		
Total liabilities and net assets		\$20,150,516	\$20,595,307		
			· · ·		

B. The following table presents condensed consolidated statements of operations for the three and six months ended December 31, 2018 and 2017.

(\$ in thousands)	Three Months Ended December 31,		Six Months Decembe				
Condensed Consolidated Statements of Operations	2018		2017		2018		2017
			(Unau	dited	d)		
Net patient services revenues	\$ 3,636,232	\$	3,607,677	\$	7,163,986	\$	7,102,487
Other	197,034		210,296		397,670		411,255
Total operating revenues	3,833,266		3,817,973		7,561,656		7,513,742
Expenses							
Salaries and employee benefits	1,822,748		1,817,466		3,583,861		3,583,453
Supplies, purchased services and other	1,759,440		1,702,423		3,490,696		3,395,223
Depreciation and amortization	205,547		207,043		412,869		432,631
Interest	82,153		76,249		163,095		151,359
Total operating expenses before restructuring, impairment and other losses	3,869,888		3,803,181		7,650,521		7,562,666
(Loss) income from operations before restructuring, impairment and other losses	(36,622)		14,792		(88,865)		(48,924)
Restructuring, impairment and other losses	20,615		16,318		41,816		30,488
Loss from operations	 (57,237)		(1,526)		(130,681)		(79,412)
Nonoperating (losses) gains	(362,813)		217,138		(214,403)		430,369
(Deficit) excess of revenues over expenses	\$ (420,050)	(	\$ 215,612	\$	(345,084)	Ç	350,957

### 1. CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with GAAP requires that management make assumptions, estimates and judgments affecting the amounts reported in the financial statements, including the notes thereto, and related disclosures of commitments and contingencies, if any. Actual results could differ materially from the estimates. A description of CHI's significant accounting policies can be found in *Note 1 of the Consolidated Interim Financial Statements (unaudited) for the Three and Six Months Ended December 31, 2018 and 2017 included in Appendix A of this Quarterly Report.* 

# PART V: MANAGEMENT'S DISCUSSION & ANALYSIS

The following table provides key balance sheet metrics as of December 31, 2018 and June 30, 2018.

Key Balance Sheet Metrics	December 31, 2018	June 30, 2018
	Unaudited	
Consolidated Balance Sheet Summary		
Total assets	\$20.2 billion	\$ 20.6 billion
Total liabilities	\$13.4 billion	\$ 13.5 billion
	\$ 6.7 billion	\$ 7.1 billion
Total net assets	Ç 3.7 SIIII SII	ψ 7.11 billion
Financial Position and Leverage Ratios (Unaudited)		
Total cash and unrestricted investments	\$5.5 billion	\$5.8 billion
Days of cash on hand <sup>1</sup>	139	149
Total debt	\$8.5 billion	\$8.5 billion
Debt to capitalization <sup>2</sup>	56.8%	55.5%

<sup>&</sup>lt;sup>1</sup> (Cash and equivalents + Investments and assets limited as to use: Internally designated investments)/((Total operating expenses before restructuring, impairment and other losses - Depreciation and amortization)/365). For the days of cash on hand, one day of operating expenses represented \$39.4 million at December 31, 2018 and \$39.1 million at June 30, 2018.

<sup>&</sup>lt;sup>2</sup> (Short-term and current portion of debt + Long-term debt)/(Short-term and current portion of debt + Long-term debt + Unrestricted net assets).

The following table presents key operating metrics and utilization statistics for CHI for the three and six months ended December 31, 2018 and 2017.

ended December 31, 2018 and 2017.		lonths Ended ember 31,	Six Month Decemb	
Key Operating Metrics and Utilization	2018	2017	2018	2017
Statistics				
Consolidated Revenues, Expenses and Key		Un	audited	
Operating Metrics			I	
Total net patient services revenues	\$ 3.6 billion	\$ 3.6 billion	\$ 7.2 billion	\$ 7.1 billion
Total operating revenues	\$ 3.8 billion	\$ 3.8 billion	\$ 7.6 billion	\$ 7.5 billion
Total operating expenses before				
restructuring, impairment and other losses	\$ 3.9 billion	\$ 3.8 billion	\$ 7.7 billion	\$ 7.6 billion
Operating EBIDA before restructuring,				
impairment and other losses <sup>1</sup>	\$ 251.1 million	\$ 298.1 million	\$ 487.1 million	\$ 535.1 million
Operating EBIDA margin before				
restructuring, impairment and other losses <sup>2</sup>	6.5%	7.8%	6.4%	7.1%
Operating (loss) income before				
restructuring, impairment and other losses	\$ (36.6) million	\$ 14.8 million	\$ (88.9) million	\$ (48.9) million
Operating (loss) income margin before				
restructuring, impairment and other losses <sup>3</sup>	(1.0)%	0.4%	(1.2)%	(0.7)%
Operating EBIDA <sup>4</sup>	\$ 230.5 million	\$ 281.8 million	\$ 445.3 million	\$ 504.6 million
Operating EBIDA margin⁵	6.0%	7.4%	5.9%	6.7%
Operating loss	\$ (57.2) million	\$ (1.5) million	\$ (130.7) million	\$ (79.4) million
Operating loss margin <sup>6</sup>	(1.5)%	(0.0)%	(1.7)%	(1.1)%
Net (loss) income <sup>7</sup>	\$ (420.1) million	\$ 215.6 million	\$ (345.1) million	\$ 351.0 million
Net (loss) income margin <sup>8</sup>	(12.1)%	5.3%	(4.7)%	4.4%
<u>Utilization Statistics</u>				
Acute admissions	110,258	119,389	221,086	237,775
Acute inpatient days	520,835	554,456	1,038,883	1,098,659
Acute average length of stay in days	4.7	4.6	4.7	4.6
Long-term care days	106,066	104,203	212,266	207,419
Medicare case-mix index	1.9	1.9	1.9	1.9
Adjusted admissions <sup>9</sup>	257,684	267,016	513,653	531,073
Inpatient ER visits	60,187	64,404	121,505	128,933
Inpatient surgeries	33,854	37,326	67,643	74,072
Outpatient ER visits	431,512	463,330	876,077	935,565
Outpatient non-ER visits	1,385,986	1,390,037	2,721,920	2,744,183
Outpatient surgeries	60,972	62,058	118,083	119,837
Physician visits	2,792,378	2,693,790	5,480,256	5,346,741

<sup>&</sup>lt;sup>1</sup>Income (loss) from operations before restructuring, impairment and other losses + depreciation and amortization + interest.

<sup>&</sup>lt;sup>2</sup> Income (loss) from operations before restructuring, impairment and other losses + depreciation and amortization + interest/total operating revenues.

<sup>&</sup>lt;sup>3</sup> Income (loss) from operations before restructuring, impairment and other losses/total operating revenues.

 $<sup>^{\</sup>rm 4}$  Income (loss) from operations + depreciation and amortization + interest.

<sup>&</sup>lt;sup>5</sup> Income (loss) from operations + depreciation and amortization + interest/total operating revenues.


<sup>&</sup>lt;sup>6</sup> Income (loss) from operations/total operating revenues.

<sup>&</sup>lt;sup>7</sup> Excess (deficit) of revenues over expenses.


<sup>&</sup>lt;sup>8</sup> Excess (deficit) of revenues over expenses/(total operating revenues + nonoperating gains (losses).


<sup>&</sup>lt;sup>9</sup> (Total gross patient revenues/total gross inpatient revenues) x acute admissions.

The following charts represent the payer gross revenue mix and healthcare services gross revenue mix for the consolidated operations as of December 31, 2018.



The following charts represent quarterly patient volume activity for the consolidated operations over the previous eight quarters on a same store basis.





# 1. SUMMARY OF OPERATING RESULTS FOR THE THREE MONTHS ENDED DECEMBER 31, 2018 AND 2017

### **OPERATING EBIDA/LOSS FROM OPERATIONS**

Operating EBIDA before restructuring, impairment and other losses declined \$47.0 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, due primarily to lower patient volumes, and unfavorable shifts in patient type and payer mix. Loss from operations before restructuring, impairment and other losses increased \$51.4 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017.

Same store net patient services revenues per adjusted admission was \$14,108 for the three months ended December 31, 2018, compared to \$13,603 for the three months ended December 31, 2017, or a \$505 and 3.7% increase. Same store expenses per adjusted admission before restructuring was \$15,022 for the three months ended December 31, 2018, compared to \$14,302 for the three months ended December 31, 2017, or a \$720 and 5.0% increase. Same store total net patient services revenues increased \$112.7 million, or 3.2%. Impacting same store net patient services revenues were \$78.7 million in contract rate increases and other revenue cycle improvements, provider fee revenue improvements of \$13.7 million, and increases in acuity of \$20.3 million; volumes remained flat. Same store total operating expenses increased \$167.2 million, or 4.5%, which includes inflationary increases as well as increased supplies, medical professional fees, and consulting expenses.

Operating EBIDA before restructuring, impairment and other losses is as follows:

	Three Months Ended December 31,		
	2018	2017	Increase (Decrease)
(\$ in millions)	Unaudited		
Operating EBIDA before restructuring, impairment and other losses	\$251.1	\$298.1	\$(47.0)
Operating EBIDA margin before restructuring, impairment and other losses, excluding transactional gains and other items	6.5%	7.8%	

Operating loss before restructuring, impairment and other losses is as follows:

	Three Months Ended December 31,		
	2018	2017	Increase (Decrease)
(\$ in millions)	Unaudit	ed	
Operating (loss) income before restructuring, impairment and other losses	\$(36.6)	\$14.8	\$(51.4)
Operating (loss) income margin before restructuring, impairment and other losses	(1.0)%	0.4%	

Operating EBIDA before restructuring, impairment and other losses, excluding transactional gains and other items, over the trailing four quarters is as follows:

(\$ in millions)	QTD 12/31/2018	QTD 9/30/2018 <i>Una</i> u	QTD 6/30/2018 udited	QTD 3/31/2018
Operating EBIDA before restructuring, impairment and other losses, excluding transactional gains and other items	\$251.1	\$236.0	\$235.1	\$259.8
Operating EBIDA margin before restructuring, impairment and other losses, excluding transactional gains and other items	6.5%	6.3%	6.3%	7.0%
Ohio compliance adjustment <sup>1</sup>	-	-	3.6	-
Operating EBIDA before restructuring, impairment and other losses	\$251.1	\$236.0	\$238.7	\$259.8
Operating EBIDA margin before restructuring, impairment and other losses	6.5%	6.3%	6.3%	7.0%

<sup>&</sup>lt;sup>1</sup> Related to a reimbursement documentation matter.

The table below presents various regional financial metrics for CHI for the three months ended December 31, 2018 and 2017. Further information on CHI's regional operating results is discussed within the regional operating trends section below.

Catholic Health Initiatives Operations Summary – Three Months Ended December 31, 2018 and 2017

Region	QTD 12/31/2018 Operating EBIDA before restructuring, impairment and other losses	QTD 12/31/2017 Operating EBIDA before restructuring, impairment and other losses	QTD 12/31/2018 Operating EBIDA margin before restructuring, impairment and other losses	QTD 12/31/2017 Operating EBIDA margin before restructuring, impairment and other losses	QTD 12/31/2018  Operating revenues percentage of CHI consolidated	QTD 12/31/2017 Operating revenues percentage of CHI consolidated
(\$ in thousands)			Unau	ıdited		
Pacific Northwest	\$58,734	\$82,667	8.3%	11.9%	18.5%	18.2%
Colorado	85,101	71,805	13.8%	11.9%	16.1%	15.8%
Texas	43,427	42,999	7.2%	7.6%	15.7%	14.8%
Nebraska	58,059	62,971	11.0%	12.1%	13.8%	13.6%
lowa	19,229	15,610	7.3%	6.0%	6.9%	6.8%
Kentucky	27,590	20,911	10.3%	7.6%	7.0%	7.2%
Ohio	(4,194)	9,343	(2.2)%	3.2%	5.1%	7.7%
Arkansas	(7,042)	427	(3.5)%	0.2%	5.3%	5.0%
North	11,792	20,034	6.3%	10.5%	4.8%	5.0%
Tennessee	18,218	19,580	10.1%	11.5%	4.7%	4.5%
National business lines <sup>1</sup>	13,301	7,200	13.7%	9.4%	2.5%	2.0%
Other <sup>2</sup>	(9,050)	(21,396)	N/A	N/A	(0.4)%	(0.6)%
Total Regional	315,165	332,151	8.2%	8.7%	100.0%	100.0%
Corporate services and other business lines <sup>3</sup>	(64,087)	(34,067)	N/A	N/A	0.0%	0.0%
Total CHI Consolidated	\$251,078	\$298,084	6.5%	7.8%	100.0%	100.0%

<sup>&</sup>lt;sup>1</sup> Includes Home Care and Senior Living business lines.

<sup>&</sup>lt;sup>2</sup> Includes the operations of Albuquerque Health Ministries and Lancaster Health Ministries MBOs as well as regional eliminations. For the three months ended December 31, 2017 results also included MedSynergies contract costs which did not occur in the current quarter end.

<sup>&</sup>lt;sup>3</sup> Includes CHI Corporate and First Initiatives Insurance, Ltd. ("FIIL"), CHI's wholly-owned captive insurance company as well as CHI system eliminations.

### **OPERATING REVENUE AND VOLUME TRENDS**

Same store total operating revenue, net patient services revenues, and other operating revenue changes are summarized below.

Three Months Ended December 31, 2018 Compared to Three Months Ended December 31, 2017

Same Store Revenue (\$ In millions)	2018	2017 Unaudited	Increase (Decrease)
Net patient services revenues	\$3,635.4	\$3,522.7	\$112.7
Other operating revenue	212.6	212.1	0.5
Total operating revenue	\$3,848.0	\$3,734.8	\$113.2

Same store patient volume increases (decreases) are summarized below.

Three Months Ended December 31, 2018 Compared to Three Months Ended December 31, 2017

	,	•
Same Store Patient Volumes	Increase (Decrease)	Increase (Decrease)
	Una	udited
Adjusted Admissions	(0.5)%	(1,283)
Acute Admissions	(4.9)%	(5,682)
Acute Inpatient Days	(3.6)%	(19,346)
Inpatient ER Visits	(6.4)%	(4,100)
Inpatient Surgeries	(7.6)%	(2,789)
Outpatient ER Visits	(2.1)%	(9,156)
Outpatient Non-ER Visits	4.1%	54,950
Outpatient Surgeries	1.5%	891
Physician Visits	3.9%	105,611

### **OPERATING EXPENSES**

Increases (decreases) in same store total operating expenses before restructuring, impairment and other losses are summarized below.

Three Months Ended December 31, 2018 Compared to Three Months Ended December 31, 2017

Same Store Expense (\$ In millions)	2018	2017	Increase (Decrease)
		Unaudited	
Total labor	\$1,822.8	\$1,767.5	\$55.3
Supplies	634.3	605.2	29.1
Purchased services	414.2	418.9	(4.7)
Medical professional fees	147.1	126.0	21.1
Interest	82.2	76.2	6.0
Depreciation and amortization	205.5	199.7	5.8
All other	<u>564.7</u>	<u>510.2</u>	<u>54.5</u>
Total operating expenses	<u>\$3,870.8</u>	<u>\$3,703.7</u>	<u>\$167.1</u>

Same store labor and supply indicators are summarized below.

Three Months Ended December 31, 2018 Compared to Three Months Ended December 31, 2017

Same store labor and supply indicators	2018	2017
	Unaudited	1
Labor % of net patient services revenues	50.1%	50.2%
		4/
Labor % of total operating expense	47.1%	47.7%
Supplies % of net patient services revenues	17.4%	17.2%
Supplies % of total operating expense	16.4%	16.3%

Same store total labor costs increased \$55.3 million, or 3.1%, for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, due to an increase in average hourly rates of \$29.3 million and an increase in FTEs of 1,058 or \$26.0 million.

Same store medical professional fees increased \$21.1 million, or 16.7%, for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, due to the movement of certain employed physicians to a professional fee contract model, primarily in the Texas region.

Same store supplies as a percentage of net patient services revenues were 17.4% for the three months ended December 31, 2018 and 17.2% for the three months ended December 31, 2017, respectively, and included \$15.0 million in increased pharmacy supplies expenses and \$14.1 million in increased medical-surgical utilization supplies expenses.

Same store interest expense increased \$6.0 million, or 7.8% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, due primarily to increased variable-rate debt interest costs as a result of rising short-term interest rates.

#### **REGIONAL OPERATING TRENDS**

The Corporation periodically reviews its allocation methodology for corporate support services and may adjust those allocations based on the strategic needs and resource consumption of the regions and CHI overall. These changes in allocation methodologies may increase or decrease a region's operating results from year to year, but have no impact on the consolidated results of CHI.

The Pacific Northwest, Colorado, Texas, Nebraska and Kentucky regions represent CHI's five largest operating regions, and for the three months ended December 31, 2018, represented 71.1% of CHI's consolidated operating revenues. Additional information on these regions is discussed below.

**Pacific Northwest** - The region's operating EBIDA before restructuring, impairment and other losses totaled \$58.7 million for the three months ended December 31, 2018, and decreased \$23.9 million, compared to the three months ended December 31, 2017. Net patient services revenues increased \$24.6 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, and included increases in volume of \$14.4 million, \$6.1 million of contract rate increases and other items, and \$4.1 million in favorable payer mix shifts.

Total net revenue per adjusted admission increased 4.9% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, while total operating expense per adjusted admission increased 8.1% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017. Total operating expenses increased \$43.3 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, due to increased labor, supplies, medical professional fees, and depreciation expenses. Total labor as a percentage of net patient services revenues increased to 51.1% for the three months ended December 31, 2018, compared to 50.1% for the three months ended December 31,

2017, which represents an unfavorable expense variance of \$6.6 million. Supply expense as a percentage of net patient services revenues increased to 14.3% for the three months ended December 31, 2018, compared to 13.4% for the three months ended December 31, 2017, which represents an unfavorable expense variance of \$6.2 million. Depreciation and amortization expenses increased \$6.0 million, or 18.8% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, due to facility expansion and renovation activities, which has increased capitalized assets and related depreciation.

**Colorado** - The region's operating EBIDA before restructuring, impairment and other losses totaled \$85.1 million for the three months ended December 31, 2018 and increased \$13.3 million compared to the three months ended December 31, 2017. Net patient services revenues increased \$11.2 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, and included \$7.7 million in increased provider fee revenue from state-based reimbursement programs, and \$9.3 million in favorable contract and acuity increases, offset by unfavorable shifts in payer mix of \$4.7 million and decreases in volume of \$1.1 million. The state-based reimbursement programs also included increased program expenses of \$3.2 million for the three months ended December 31, 2018 and provided an overall operating EBIDA increase of \$4.5 million compared to the three months ended December 31, 2017.

Total net revenue per adjusted admission increased 2.7% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, while total operating expense per adjusted admission increased 1.6% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017. Operating expenses increased \$4.6 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017. Total labor as a percentage of net patient services revenues decreased to 38.9% for the three months ended December 31, 2018, compared to 41.3% for the three months ended December 31, 2017, representing a favorable expense variance of \$14.3 million. Supply expense as a percentage of net patient services revenues increased to 15.3% for the three months ended December 31, 2018, compared to 14.9% for the three months ended December 31, 2017, which represents an unfavorable expense variance of \$2.5 million.

**Texas** - The region's operating EBIDA before restructuring, impairment and other losses totaled \$43.4 million for the three months ended December 31, 2018 and increased \$0.4 million compared to the three months ended December 31, 2017. Operating results for the three months ended December 31, 2017 included \$14.6 million of insurance recoveries recorded related to the impact of Hurricane Harvey that occurred during the first quarter of fiscal year 2018. Net patient services revenues increased \$43.6 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, and included \$22.1 million in contract rate increases and revenue cycle improvements, \$18.4 million of managed care and government settlements, and increases in volume of \$5.1 million, offset by \$2.0 million in decreased provider fee revenue from state-based reimbursement programs. The state-based reimbursement programs also included increased program expenses of \$4.6 million for the three months ended December 31, 2018 and provided an overall operating EBIDA decrease of \$6.6 million compared to the three months ended December 31, 2017.

Total net revenue per adjusted admission increased 6.8% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, while total operating expense per adjusted admission increased 3.7% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017. Total operating expenses increased \$28.4 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, as a result of growth in patient volumes and inflationary increases, slightly offset by continued implementation of expense management and productivity improvements across the region. Total labor as a percentage of net patient services revenues decreased to 42.2% for the three months ended December 31, 2018, compared to 43.3% for the three months ended December 31, 2017, representing a favorable expense variance of \$6.4 million. However, medical professional fees expense increased \$8.9 million and purchased services expense increased \$9.4 million for the three months ended December 31, 2018,

compared to the three months ended December 31, 2017, due to a shift in classification of certain services and physician compensation arrangements. Supply expense as a percentage of net patient services revenues decreased to 18.0% for the three months ended December 31, 2018, compared to 19.7% for the three months ended December 31, 2017, representing a favorable expense variance of \$9.7 million.

**Nebraska** - The region's operating EBIDA before restructuring, impairment and other losses totaled \$58.1 million for the three months ended December 31, 2018 and decreased \$4.9 million compared to the three months ended December 31, 2017. Net patient services revenues increased \$5.7 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, and included \$20.0 million in favorable contract rate increases and revenue cycle improvements, and favorable payer mix shifts of \$5.0 million, offset by decreases in volume of \$19.3 million.

Total net revenue per adjusted admission increased 2.4% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, while total operating expense per adjusted admission increased 3.0% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017. Total operating expenses increased \$8.3 million for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, due to increased labor, medical professional fees, and rental expenses. Total labor as a percentage of net patient services revenues increased to 54.5% for the three months ended December 31, 2018, compared to 54.0% for the three months ended December 31, 2017, representing an unfavorable expense variance of \$2.1 million. Supply expense as a percentage of net patient services revenues decreased to 15.2% for the three months ended December 31, 2018, compared to 15.3% for the three months ended December 31, 2017, representing a favorable expense variance of \$0.3 million.

**Kentucky** - The region's operating EBIDA before restructuring, impairment and other losses (excluding discontinued operations) totaled \$27.6 million for the three months ended December 31, 2018 and increased \$6.7 million compared to the three months ended December 31, 2017. Net patient services revenues decreased \$8.7 million (on a same store basis) for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, and included volume decreases of \$11.2 million, and unfavorable shifts in service mix of \$8.4 million, offset by acuity improvements of \$2.1 million and \$8.8 million in favorable contract rate increases and other items. The majority of the volume decreases is related to the transfer of certain homecare operations to another CHI affiliate. Total operating expenses decreased \$8.8 million (on a same store basis) for the three months ended December 31, 2018, compared to the three months ended December 31, 2017.

Total net revenue per adjusted admission increased 2.9% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017, while total operating expense per adjusted admission increased 2.6% for the three months ended December 31, 2018, compared to the three months ended December 31, 2017. Total labor as a percentage of net patient services revenues decreased to 46.0% for the three months ended December 31, 2018, compared to 47.2% for the three months ended December 31, 2017, representing a favorable expense variance of \$2.9 million. Supply expense as a percentage of net patient services revenues increased to 21.0% for the three months ended December 31, 2018, compared to 19.5% for the three months ended December 31, 2017, representing an unfavorable expense variance of \$3.6 million.

CHI Corporate services and other business lines - Operating EBIDA losses before restructuring, impairment and other losses totaled \$64.1 million for three months ended December 31, 2018 and increased \$30.0 million compared to the three months ended December 31, 2017. The increased loss is due primarily to a \$17.0 million reduction in the self-insurance programs due to favorable reserve adjustments in the prior year, and overall increases of \$13.0 million in corporate support service functions. Changes in support services activities relate to a variety of factors, including strategic transfers of support activities from the regions and other service lines to corporate services to build corporate support functions, and new implementations of system-wide services. Support services allocations to the regions consider the strategic needs and resource consumption of the regions and CHI

overall. Expense decreases have occurred within various support services concentrated within Information Technology, Clinical Engineering and Onshore Risk and Insurance.

Restructuring, Impairment and Other Losses

	Three Months Ended December 31,	
	2018	2017
(\$ in thousands)	Unaudit	ed
Changes in business operations	\$15,867	\$10,467
Severance costs	2,130	3,590
Impairment charges	<u>2,618</u>	<u>2,261</u>
Total restructuring, impairment and other losses	<u>\$20,615</u>	<u>\$16,318</u>
Non-cash expenses related to restructuring, impairment and other		
losses	<u>\$2,618</u>	<u>\$2,261</u>

Restructuring, impairment, and other losses include charges relating to changes in business operations, severance costs, long-lived asset impairments and acquisition-related costs. Changes in business operations include costs incurred periodically to implement reorganization efforts within specific operations to align CHI's operations more cost effectively. The non-cash portion of total restructuring, impairment and other losses includes impairment charges.

**Nonoperating Results** 

	Three Months Ended December 31, 2018 2017	
(\$ in thousands)		Unaudited
Investment (losses) gains, net	\$(330,689)	\$198,691
Realized and unrealized (losses) gains on interest rate swaps	(29,754)	12,307
Other nonoperating (losses) gains	(2,370)	<u>6,140</u>
Total nonoperating (losses) gains	<u>\$(362,813)</u>	<u>\$217,138</u>

# 2. SUMMARY OF OPERATING RESULTS FOR THE SIX MONTHS ENDED DECEMBER 31, 2018 AND 2017

### **OPERATING EBIDA/LOSS FROM OPERATIONS**

Operating EBIDA before restructuring, impairment and other losses, excluding transactional gains and other items, declined \$37.7 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due primarily to lower patient volumes, and unfavorable shifts in patient type and payer mix. Loss from operations before restructuring, impairment and other losses, excluding transactional gains and other items, increased \$49.8 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017.

Same store net patient services revenues per adjusted admission was \$13,945 for the six months ended December 31, 2018, compared to \$13,468 for the six months ended December 31, 2017, or a \$477 and 3.5% increase. Same store expenses per adjusted admissions before restructuring was \$14,896 for the six months ended December 31, 2018, compared to \$14,319 for the six months ended December 31, 2017, or a \$577 and 4.0% increase. Same store total net patient services revenues increased \$233.3 million, or 3.4%. Impacting same store net patient services revenues were \$93.4 million in contract rate increases, \$97.2 million of revenue cycle and other improvements, provider fee revenue improvements of \$45.3 million, increases in acuity of \$16.6 million, and increased volumes of \$14.3 million, offset by service mix declines of \$33.5 million. Same store total operating expenses increased \$283.9

million, or 3.9%, which includes inflationary increases as well as increased supplies, medical professional fees, and consulting expenses.

Operating EBIDA before restructuring, impairment and other losses, excluding transactional gains and other items, is as follows:

	Six Months Ended December 31,		
	2018	2017	Increase (Decrease)
(\$ in millions)	Unau	ıdited	, , , , , , , , , , , , , , , , , , , ,
Operating EBIDA before restructuring, impairment and other losses, excluding transactional gains and other items	\$487.1	\$524.8	\$(37.7)
Operating EBIDA margin before restructuring, impairment and other losses, excluding transaction gains and other items	6.4%	7.0%	
Nebraska net patient services revenue adjustments <sup>1</sup>		13.6	
Ohio compliance adjustment <sup>2</sup>	-	(7.3)	
Gains on real estate sales		4.0	_
Operating EBIDA before restructuring, impairment and other losses	\$487.1	\$535.1	\$(48.0)
Operating EBIDA margin before restructuring, impairment and other losses	6.4%	7.1%	_

<sup>&</sup>lt;sup>1</sup> Related to favorable bad debt adjustments.

Operating loss before restructuring, impairment and other losses, excluding transactional gains and other items impacting operations, is as follows:

	Six Months Ended December 31,		
	2018	2017	Increase (Decrease)
(\$ in millions)	Una	udited	,,
Operating loss before restructuring, impairment and other losses, excluding transactional gains and other items	\$(88.9)	\$(39.1)	\$(49.8)
Operating loss margin before restructuring, impairment and other losses, excluding transactional gains and other items	(1.2)%	(0.5)%	
Nebraska net patient services revenue adjustments <sup>1</sup>	-	13.6	
Ohio compliance adjustment <sup>2</sup>	-	(7.3)	
Gains on real estate sales	-	4.0	
Depreciation increase on IT assets due to change in useful life	-	(20.1)	
Operating loss before restructuring, impairment and other losses	\$(88.9)	\$(48.9)	\$(40.0)
Operating loss margin before restructuring, impairment and other losses	(1.2)%	(0.7)%	

<sup>&</sup>lt;sup>1</sup> Related to favorable bad debt adjustments.

 $<sup>^{\</sup>rm 2}$  Related to a reimbursement documentation matter.

 $<sup>^{\</sup>rm 2}$  Related to a reimbur sement documentation matter.

The table below presents various regional financial metrics for CHI for the six months ended December 31, 2018 and 2017. Further information on CHI's regional operating results is discussed within the regional operating trends section below.

Catholic Health Initiatives Operations Summary – Six Months Ended December 31, 2018 and 2017

Region	YTD 12/31/2018 Operating EBIDA before restructuring, impairment and other losses	YTD 12/31/2017 Operating EBIDA before restructuring, impairment and other losses	YTD 12/31/2018 Operating EBIDA margin before restructuring, impairment and other losses	YTD 12/31/2017 Operating EBIDA margin before restructuring, impairment and other losses	YTD 12/31/2018  Operating revenues percentage of CHI consolidated	YTD 12/31/2017 Operating revenues percentage of CHI consolidated
(\$ in thousands)			Unaudited			
Pacific Northwest	\$127,992	\$155,548	9.1%	11.4%	18.6%	18.2%
Colorado	170,989	141,003	13.9%	11.8%	16.3%	15.9%
Texas	79,349	38,873	6.7%	3.6%	15.6%	14.4%
Nebraska	80,877	129,114	7.9%	12.5%	13.6%	13.7%
Iowa	36,200	29,284	6.9%	5.7%	6.9%	6.8%
Kentucky	47,932	52,449	9.2%	9.5%	6.9%	7.3%
Ohio	8,032	13,857	2.0%	2.4%	5.3%	7.5%
Arkansas	(17,165)	2,867	(4.3)%	0.8%	5.3%	5.0%
North Dakota/Minnesota	18,833	39,189	5.2%	10.4%	4.8%	5.0%
Tennessee	30,114	33,094	8.6%	10.0%	4.6%	4.4%
National business lines <sup>1</sup>	22,633	14,763	11.9%	10.0%	2.5%	2.0%
Other <sup>2</sup>	(10,172)	(41,213)	N/A	N/A	(0.4)%	(0.2)%
Total Regional	595,614	608,828	7.9%	8.1%	100.0%	100.0%
Corporate services and other business lines <sup>3</sup>	(108,515)	(73,762)	N/A	N/A	0.0%	0.0%
Total CHI Consolidated	\$487,099	\$535,066	6.4%	7.1%	100.0%	100.0%

<sup>&</sup>lt;sup>1</sup> Includes Home Care and Senior Living business lines.

### **OPERATING REVENUE AND VOLUME TRENDS**

Same store total operating revenue, net patient services revenues, and other operating revenue changes are summarized below. Normalized amounts have been adjusted to exclude transactional gains and other items as noted above.

Six Months Ended December 31, 2018 Compared to Six Months Ended December 31, 2017

Same Store Revenue (\$ In millions)	2018	2017 Unaudited	Increase (Decrease)
Net patient services revenues	\$7,162.8	\$6,929.5	\$233.3
Other operating revenue	416.5	415.7	0.8
Total operating revenue	7,579.3	7,345.2	234.1
Net patient services revenues normalized¹	7,162.8	6,925.9	236.9
Other operating revenue normalized <sup>2</sup>	<u>416.5</u>	<u>409.0</u>	<u>7.5</u>
Total operating revenue normalized	\$7,579.3	\$7,334.9	\$244.4

<sup>&</sup>lt;sup>1</sup> Excludes the \$13.6 million Nebraska favorable bad debt adjustments for the three months ended September 30, 2017 and the \$10.1 million Ohio unfavorable reimbursement documentation matter impact for the six months ended December 31, 2017.

<sup>&</sup>lt;sup>2</sup> Includes the operations of Albuquerque Health Ministries and Lancaster Health Ministries MBOs as well as regional eliminations. For the six months ended December 31, 2017 results also included MedSynergies contract costs which did not occur in the current period.

<sup>3</sup> Includes CHI Corporate and First Initiatives Insurance, Ltd. ("FIIL"), CHI's wholly-owned captive insurance company as well as CHI system eliminations.

<sup>&</sup>lt;sup>2</sup> Excludes the \$2.7 million favorable JOA income share impact as a result of the Ohio reimbursement documentation matter for the three months ended September 30, 2017 and the \$4.0 in real estate gains for the six months ended December 31, 2017.

Same store patient volume increases (decreases) are summarized below.

Six Months Ended December 31, 2018 Compared to Six Months Ended December 31, 2017

<u> </u>	•	-
Same Store Patient Volumes	Increase (Decrease)	Increase (Decrease)
	Unat	ıdited
Adjusted Admissions	(0.2)%	(869)
Acute Admissions	(4.2)%	(9,594)
Acute Inpatient Days	(2.9)%	(30,932)
Inpatient ER Visits	(5.6)%	(7,202)
Inpatient Surgeries	(6.9)%	(4,993)
Outpatient ER Visits	(1.5)%	(13,669)
Outpatient Non-ER Visits	3.7%	96,315
Outpatient Surgeries	2.0%	2,334
Physician Visits	2.8%	147,090

### **OPERATING EXPENSES**

Increases (decreases) in same store total operating expenses before restructuring, impairment and other losses are summarized below.

Six Months Ended December 31, 2018 Compared to Six Months Ended December 31, 2017

OIX MONEIS Ended December 5	e, eeee companea to em:		,
Same Store Expense	2018	2017	Increase
(\$ In millions)			(Decrease)
		Unaudited	
Total labor	\$3,583.8	\$3,484.3	\$99.5
Supplies	1,246.6	1,184.3	62.3
Purchased services	836.5	834.2	2.3
Medical professional fees	285.7	241.7	44.0
Interest	163.1	151.3	11.8
Depreciation and amortization	412.9	418.0	(5.1)
All other	<u>1,122.8</u>	<u>1,053.7</u>	<u>69.1</u>
Total operating expenses	<u>\$7,651.4</u>	<u>\$7,367.5</u>	<u>\$283.9</u>

Same store labor and supply indicators are summarized below.

Six Months Ended December 31, 2018 Compared to Six Months Ended December 31, 2017

Same store labor and supply indicators	2018	2017
	Unaudite	d
Labor % of net patient services revenues	50.0%	50.3%
Labor % of total operating expense	46.8%	47.3%
Supplies % of net patient services revenues	17.4%	17.1%
Supplies % of total operating expense	16.3%	16.1%

Same store total labor costs increased \$99.5 million, or 2.9%, for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due to an increase in average hourly rates of \$69.0 million and an increase in FTEs of 633 or \$30.5 million.

Same store medical professional fees increased \$44.0 million, or 18.2%, for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due to the movement of certain employed physicians to a professional fee contract model, primarily in the Texas region.

Same store supplies as a percentage of net patient services revenues were 17.4% for the six months ended December 31, 2018 and 17.1% for the six months ended December 31, 2017, respectively, and included \$42.6 million in increased medical-surgical utilization supplies expenses and \$19.7 million in increased pharmacy supplies expenses.

Same store interest expense increased \$11.8 million, or 7.8% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due largely to increased variable-rate debt interest costs as a result of rising short-term interest rates. Total debt outstanding decreased \$73.5 million during the six months ended December 31, 2018, due to regularly scheduled debt service payments.

Same store depreciation and amortization expenses decreased \$5.1 million, or 1.2% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017 as a result of \$20.1 million in increased expenses in the prior year period due to changes in the estimated remaining useful life of certain information technology assets.

### **REGIONAL OPERATING TRENDS**

The Corporation periodically reviews its allocation methodology for corporate support services and may adjust those allocations based on the strategic needs and resource consumption of the regions and CHI overall. These changes in allocation methodologies may increase or decrease a region's operating results from year to year, but have no impact on the consolidated results of CHI.

The Pacific Northwest, Colorado, Texas, Nebraska and Kentucky regions represent CHI's five largest operating regions, and for the six months ended December 31, 2018, represented 71.0% of CHI's consolidated operating revenues. Additional information on these regions is discussed below.

**Pacific Northwest** - The region's operating EBIDA before restructuring, impairment and other losses totaled \$128.0 million for the six months ended December 31, 2018, and decreased \$27.6 million, compared to the six months ended December 31, 2017. Net patient services revenues increased \$47.7 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, and included \$23.2 million in favorable contract increases, \$14.6 million of revenue cycle improvements and increases in volume of \$9.9 million.

Total net revenue per adjusted admission increased 4.0% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, while total operating expense per adjusted admission increased 6.5% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017. Total operating expenses increased \$78.4 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due to increased labor, supplies, medical professional fees, and depreciation expenses. Total labor as a percentage of net patient services revenues increased to 50.9% for the six months ended December 31, 2018, compared to 50.2% for the six months ended December 31, 2017, which represents an unfavorable expense variance of \$9.4 million. Supply expense as a percentage of net patient services revenues increased to 13.8% for the six months ended December 31, 2018, compared to 13.5% for the six months ended December 31, 2017, which represents an unfavorable expense variance of \$5.0 million. Depreciation and amortization expenses increased \$12.9 million, or 20.4% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due to facility expansion and renovation activities, which have increased capitalized assets and related depreciation.

**Colorado** - The region's operating EBIDA before restructuring, impairment and other losses totaled \$171.0 million for the six months ended December 31, 2018 and increased \$30.0 million compared to the six months ended December 31, 2017. Total other operating revenues increased \$23.9 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due primarily to increased medical premium revenues. Net patient services revenues increased \$10.9 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, and included \$14.8 million in favorable contract and acuity

increases, and \$1.5 million in increased provider fee revenue from state-based reimbursement programs, offset by decreases in volume of \$5.4 million. The state-based reimbursement programs also included increased program expenses of \$4.6 million for the six months ended December 31, 2018 and provided an overall operating EBIDA decrease of \$3.1 million compared to the six months ended December 31, 2017.

Total net revenue per adjusted admission increased 2.5% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, while total operating expense per adjusted admission increased 2.6% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017. Operating expenses increased \$11.5 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017. Total labor as a percentage of net patient services revenues decreased to 38.5% for the six months ended December 31, 2017, representing a favorable expense variance of \$22.0 million. Supply expense as a percentage of net patient services revenues increased to 15.2% for the six months ended December 31, 2018, compared to 14.7% for the six months ended December 31, 2017, which represents an unfavorable expense variance of \$5.4 million.

**Texas** - The region's operating EBIDA before restructuring, impairment and other losses totaled \$79.3 million for the six months ended December 31, 2018 and increased \$40.5 million compared to the six months ended December 31, 2017. Operating results for the six months ended December 31, 2017 were impacted by Hurricane Harvey in August 2017, which resulted in a decrease of \$25.8 million to total operations as a result of decreased patient volumes due to rescheduling of procedures and visits, increased labor costs due to overtime and paid time off granted to employees, but partially offset by \$14.6 million of insurance recoveries which were primarily funded by FIIL. Net patient services revenues increased \$113.4 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, and included, increases in volume of \$33.0 million, \$24.9 million in increased provider fee revenue from state-based reimbursement programs, \$24.9 million in managed care and government payer settlements, \$16.0 million in contract rate increases, and \$14.6 million in revenue cycle improvements. The state-based reimbursement programs also included increased program expenses of \$10.1 million for the six months ended December 31, 2018 and provided an overall operating EBIDA increase of \$14.8 million compared to the six months ended December 31, 2017.

Total net revenue per adjusted admission increased 7.4% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, while total operating expense per adjusted admission increased 0.9% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017. Total operating expenses increased \$47.7 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, as a result of growth in patient volumes and inflationary increases, slightly offset by continued implementation of expense management and productivity improvements across the region. Total labor as a percentage of net patient services revenues decreased to 41.6% for the six months ended December 31, 2018, compared to 45.5% for the six months ended December 31, 2017, representing a favorable expense variance of \$44.7 million. However, medical professional fees expense increased \$22.2 million and purchased services expense increased \$19.6 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due to a shift in classification of certain services and physician compensation arrangements. Supply expense as a percentage of net patient services revenues decreased to 18.5% for the six months ended December 31, 2018, compared to 19.7% for the six months ended December 31, 2017, representing a favorable expense variance of \$14.2 million.

**Nebraska** - The region's operating EBIDA before restructuring, impairment and other losses totaled \$80.9 million for the six months ended December 31, 2018 and decreased \$48.2 million compared to the six months ended December 31, 2017. Results for the six months ended December 31, 2017 included \$13.6 million in favorable net patient services revenues adjustments and \$4.0 million in real estate gains. Net patient services revenues decreased \$7.7 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, and included decreases in volume of \$30.3 million, \$15.2 million of unfavorable service mix shifts and the \$13.6

million favorable adjustment to net patient services revenues in the prior year period that did not recur in the current year period, offset by \$14.4 million in favorable contract rate increases and \$37.0 million of revenue cycle and other improvements.

Total net revenue per adjusted admission decreased 0.1% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, while total operating expense per adjusted admission increased 4.0% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017. Total operating expenses increased \$31.4 million for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, due to increased labor, medical professional fees, and rental expenses. Total labor as a percentage of net patient services revenues increased to 56.0% for the six months ended December 31, 2018, compared to 53.7% for the six months ended December 31, 2017, representing an unfavorable expense variance of \$21.6 million. Supply expense as a percentage of net patient services revenues increased to 15.9% for the six months ended December 31, 2018, compared to 15.6% for the six months ended December 31, 2017, representing an unfavorable expense variance of \$3.2 million.

**Kentucky** - The region's operating EBIDA before restructuring, impairment and other losses (excluding discontinued operations) totaled \$47.9 million for the six months ended December 31, 2018 and decreased \$4.5 million compared to the six months ended December 31, 2017. Net patient services revenues decreased \$21.8 million (on a same store basis) for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, and included volume decreases of \$40.1 million, offset by acuity improvements of \$5.9 million, \$5.2 million in favorable contract rate increases and \$7.2 million in revenue cycle and other improvements. The majority of the volume decreases is related to the transfer of certain homecare operations to another CHI affiliate. Total operating expenses decreased \$17.3 million (on a same store basis) for the six months ended December 31, 2018, compared to the six months ended December 31, 2017.

Total net revenue per adjusted admission increased 2.5% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017, while total operating expense per adjusted admission increased 3.1% for the six months ended December 31, 2018, compared to the six months ended December 31, 2017. Total labor as a percentage of net patient services revenues decreased to 45.9% for the six months ended December 31, 2018, compared to 46.1% for the six months ended December 31, 2017, representing a favorable expense variance of \$1.0 million. Supply expense as a percentage of net patient services revenues increased to 20.6% for the six months ended December 31, 2018, compared to 19.0% for the six months ended December 31, 2017, representing an unfavorable expense variance of \$7.6 million.

CHI Corporate services and other business lines - Operating EBIDA losses before restructuring, impairment and other losses totaled \$108.5 million for six months ended December 31, 2018 and increased \$34.8 million compared to the six months ended December 31, 2017. The increased loss is due primarily to a \$8.1 million reduction in the self-insurance programs due to favorable reserve adjustments in the prior year, and overall increases of \$26.7 million in corporate support service functions. Changes in support services activities relate to a variety of factors, including strategic transfers of support activities from the regions and other service lines to corporate services to build corporate support functions, and new implementations of system-wide services. Support services allocations to the regions consider the strategic needs and resource consumption of the regions and CHI overall. Expense decreases have occurred within various support services concentrated within Information Technology, Clinical Engineering and Onshore Risk and Insurance.

Restructuring, Impairment and Other Losses

	·	
	Six Months Ended December 31,	
	2018	2017
(\$ in thousands)	Unauc	lited
Changes in business operations	\$32,796	\$18,406
Severance costs	5,723	9,615
Impairment charges	<u>3,297</u>	<u>2,467</u>
Total restructuring, impairment and other losses	<u>\$41,816</u>	<u>\$30,488</u>
Non-cash expenses related to restructuring, impairment and other		
losses	<u>\$3,297</u>	<u>\$2,467</u>

Restructuring, impairment, and other losses include charges relating to changes in business operations, severance costs, long-lived asset impairments and acquisition-related costs. Changes in business operations include costs incurred periodically to implement reorganization efforts within specific operations to align CHI's operations more cost effectively. The non-cash portion of total restructuring, impairment and other losses includes impairment charges.

### **Nonoperating Results**

	Six Months Ended December 31,	
	2018	2017
(\$ in thousands)		Unaudited
Investment (losses) gains, net	\$(192,358)	\$413,628
Gains on early extinguishment of debt	-	208
Realized and unrealized (losses) gains on interest rate swaps	(15,801)	8,325
Other nonoperating (losses) gains	<u>(6,244)</u>	<u>8,208</u>
Total nonoperating (losses) gains	<u>\$(214,403)</u>	<u>\$430,369</u>

# 3. SUMMARY OF CHI BALANCE SHEETS AS OF DECEMBER 31, 2018 AND JUNE 30, 2018

Total assets were \$20.2 billion and \$20.6 billion at December 31, 2018 and June 30, 2018, respectively, representing a decrease of 2.2%, or \$444.8 million, during the six months ended December 31, 2018. The decrease was attributable primarily to a decrease of \$361.8 million in cash and unrestricted investments, which includes investment losses of \$192.4 million during the six months ended December 31, 2018.

Total cash and equivalents, and unrestricted investments were \$5.5 billion and \$5.8 billion at December 31, 2018 and June 30, 2018, respectively, representing a decrease of 6.2%, or \$361.8 million during the six months ended December 31, 2018. CHI spent a net \$329.6 million in investing cash flow activities, including \$287.5 million of ongoing capital investment activity, which include IT infrastructure investments, as well as new hospital construction and facility renovations across CHI during the six months ended December 31, 2018. Financing cash flow decreases for the six months ended December 31, 2018 totaled \$96.6 million and includes net debt and interest payments and net swap collateral payments. Working capital changes and cash flows from operations, including investments and assets limited to use, increased \$64.4 million for the six months ended December 31, 2018.

Days of cash on hand decreased to 139 days at December 31, 2018, from 149 at June 30, 2018. For purposes of the days of cash on hand calculation, one day of operating expenses represented \$39.4 million and \$39.1 million at December 31, 2018 and June 30, 2018, respectively.

Net patient accounts receivable of \$2.2 billion and \$2.1 billion at December 31, 2018 and June 30, 2018, respectively, represented a slight increase of 2.0%, or \$42.8 million, during the six months ended December 31,

2018. Total liabilities were \$13.4 billion and \$13.5 billion at December 31, 2018 and June 30, 2018, respectively, representing a slight decrease of 0.4%, or \$49.4 million, during the six months ended December 31, 2018.

Total debt was \$8.5 billion at both December 31, 2018 and June 30, 2018 and includes a decrease of \$73.5 million due to regularly scheduled debt service payments during the six months ended December 31, 2018.

The debt-to-capitalization ratio increased to 56.8% at December 31, 2018, from 55.5% at June 30, 2018. Total unrestricted net assets decreased 5.9%, or \$402.9 million during the six months ended December 31, 2018, due primarily to \$345.1 million in deficit of revenues over expenses, which includes investment losses of \$192.4 million and a \$36.5 million net loss from discontinued operations.

### 4. CERTAIN CONTRACTUAL OBLIGATIONS

#### CAPITAL OBLIGATION DOCUMENT

The obligations of the Corporation to pay amounts due on its commercial paper notes, revenue bonds, guarantees and certain swap agreements are evidenced by Obligations issued under the Capital Obligation Document ("COD"). Obligations also evidence the Corporation's obligations to banks that provide funds for the purchase of indebtedness tendered for purchase or subject to mandatory tender for purchase and not remarketed under the Corporation's self-liquidity program, funded loans and for general purpose revolving lines of credit.

At December 31, 2018, the Corporation's outstanding indebtedness evidenced by Obligations issued under the COD totaled \$7.9 billion. Payment obligations under the COD are limited to the Obligated Group (defined in the COD), which only includes the Corporation. Certain covenants under the COD are tested based on the combination of the Obligated Group and Participants. However, holders of Obligations have no recourse to Participants or their property for payment thereof.

#### **INDEBTEDNESS**

(\$ in millions)	December 31, 2018
COD Debt	2010
Fixed Rate Bonds <sup>1</sup>	\$ 4,208
Variable Rate Bonds <sup>2</sup>	508
Long Term Rate Bonds <sup>3</sup>	142
Direct Purchase Bonds <sup>4</sup>	1,905
Commercial Paper Notes	881
Short term bank loans and lines of credit <sup>5</sup>	<u>250</u>
Total COD Debt	\$ 7,894
Non-COD Debt	
Other MBO Debt <sup>6</sup>	\$ 358
Capital Leases	107
Note Payable	<u>99</u>
Total Non-COD Debt	<u>\$ 564</u>
Total CHI Debt	\$ 8,458

<sup>&</sup>lt;sup>1</sup> Excludes unamortized original issue premium, discount and issuance costs.

<sup>&</sup>lt;sup>2</sup> Includes bonds that bear interest at variable rates (currently determined weekly) and are subject to optional tender for purchase by their holders, FRNs that bear interest at variable rates (currently determined weekly and monthly), for a specified period and are subject to mandatory tender as set forth below and direct purchase debt of affiliates that is placed directly with holders, bears interest at variable rates determined monthly based upon a percentage of LIBOR or SIFMA plus a spread, and is subject to mandatory tender on certain dates.

<sup>&</sup>lt;sup>3</sup> Long-term rate bonds bear interest at a fixed rate for a specified period and are subject to mandatory tender at the end of such period as set forth below.

<sup>&</sup>lt;sup>4</sup> Direct purchase debt of the Corporation is placed directly with holders, bears interest at variable rates determined monthly based upon a percentage of LIBOR or SIFMA plus a spread, and is subject to mandatory tender on certain dates as set forth below.

<sup>&</sup>lt;sup>5</sup> Excludes a revolving line of credit with BNY Mellon in the amount of \$69 million, with an expiration date of June 28, 2019. As of December 31, 2018, the line was undrawn.

<sup>6</sup> Other MBO debt is comprised primarily of \$ 171.4 million of CHI St. Luke's affiliate debt, \$ 90.4 million of Centura affiliate debt and \$39.6 million of St. Leonard Master Trust Indenture debt.

The required principal payments on the total CHI long-term debt during fiscal year 2019 is approximately \$697.7 million.

As of December 31, 2018, the Corporation had one revolving line of credit with PNC Bank in the amount of \$250 million that is fully drawn and matures on July 3, 2019.

### A. Direct Purchase Debt

The Corporation's direct purchase debt is subject to mandatory tender on the dates set forth in the following table. Prior to the mandatory tender of direct purchase debt, management expects that it would analyze the then current market conditions and availability and relative cost of refinancing or restructuring alternatives which could include without limitation, conversion to another interest mode, refinancing or repayment.

(\$ in millions)	Par Outstanding	Mandatory
Series	December 31, 2018	Tender Date
Taxable 2018B	\$200.0	8/30/2019
Colorado 2011C¹	117.0	9/30/2019
Providence Series 2009A	6.3	10/1/2019
Providence Series 2009B	5.4	10/1/2019
Providence Series 2009C	3.8	10/1/2019
Colorado 2017B <sup>1</sup>	333.7	12/3/2019
Washington 2008A <sup>1</sup>	118.1	1/29/2020
Colorado 2004B6 <sup>1</sup>	54.2	9/25/2020
Taxable 2013E	125.0	12/18/2020
Taxable 2013F	75.0	12/18/2020
St. Joseph Series 2014	25.3	5/1/2021
Taxable 2017A	250.0	7/1/2021
Colorado 2015-1	35.0	8/1/2021
Colorado 2015-2	63.5	8/1/2021
Taxable 2018A	275.0	8/2/2021
St. Claire Series 2010	29.7	6/1/2022
Colorado 2013C	100.0	12/18/2023
Colorado 2015A	15.6	8/1/2024
Colorado 2015B	27.3	8/1/2024
Washington 2015A	<u>45.4</u>	8/3/2024
Total	<u>\$ 1,905.3</u>	

Includes a "term out" provision that varies among agreements, which permits repayment after the mandatory tender date absent any defaults or events of default.

The Corporation's direct purchase agreements are publicly available, and can be accessed through the Digital Assurance Certification LLC website ("DAC") at <a href="www.dacbond.com">www.dacbond.com</a> and the Municipal Securities Rulemaking Board ("MSRB") through the Electronic Municipal Market Access ("EMMA") website of the MSRB, which can be found at <a href="http://emma.msrb.org">http://emma.msrb.org</a>.

# B. Long - Term Rate Bonds

The Corporation's long-term rate bonds are subject to mandatory tender on the dates set forth below. Prior to the mandatory tender of long-term rate bonds, management expects that it would analyze the then current market conditions and availability and relative cost of refinancing or restructuring alternatives, which could include without limitation, conversion to another interest mode, refinancing or repayment.

(\$ in millions)	Par Outstanding	Mandatory
Series	December 31, 2018	Tender Date
CO 2009B-3	\$40.0	11/6/2019
KY 2009B	60.0	11/10/2021
CO 2008D-3	<u>41.9</u>	11/12/2021
Total Long-Term Rate Bonds	<u>\$141.9</u>	

# C. Floating Rate Notes ("FRNs")

The Corporation's FRNs are subject to mandatory tender on the dates set forth below. Prior to the mandatory tender of the FRNs, management expects that it would analyze the then current market conditions and availability and relative cost of refinancing or restructuring alternatives, which could include without limitation, conversion to another interest mode, refinancing or repayment.

(\$ in millions)	Par Outstanding	Mandatory
Series	December 31, 2018	Tender Date
KY 2011B-1	\$52.7	2/1/2020
KY 2011B-2	52.7	2/1/2020
CO 2008C-2	26.5	11/12/2020
CO 2008C-4	26.5	11/12/2020
WA 2013B-1	100.0	1/1/2021
WA 2013B-2	100.0	1/1/2025
KY 2011B-3	<u>52.7</u>	2/1/2025
Total FRNs	<u>\$411.1</u>	

### D. Variable Rate Bonds

The Corporation's variable rate demand bonds are subject to optional and mandatory tender. As of December 31, 2018, variable rate demand bonds are outstanding in the amount of \$96.7 million, supported by the Corporation's self-liquidity, not by a dedicated liquidity or credit facility. See *Part V: 5. Liquidity and Capital Resources - Liquidity Arrangements*.

# E. Taxable Commercial Paper

The Corporation's commercial paper note program permits the issuance of up to \$881 million in aggregate principal amount outstanding, with maturities limited to 270-day periods. The Corporation has directed the commercial paper dealers to tranche the commercial paper maturities so that no greater than approximately one-third of the outstanding balance matures in any one month, and no more than \$100 million matures per dealer within any five business-day period while the outstanding balance of the commercial paper is greater than \$500 million. The Corporation has, from time to time, directed its dealers to deviate from such directions, and may do so again in the future. As of December 31, 2018, \$881 million of commercial paper notes were outstanding. The commercial paper notes are supported by the Corporation's self-liquidity, and not supported by a dedicated liquidity or credit facility. See *Part V: 5. Liquidity and Capital Resources - Liquidity Arrangements*.

# F. Swap Agreements

The Corporation or its affiliates are currently party to 34 swap transactions that had an aggregate notional amount of approximately \$1.5 billion at December 31, 2018. The 34 transactions have varying termination dates ranging from 2019 to 2047. The swap agreements require the Corporation (or with respect to certain swap agreements, affiliates of the corporation) to provide collateral if its respective liability, determined on a mark-to-market basis, exceeds a specified threshold that varies based upon the rating on the Corporation's long-term indebtedness. The swap agreements of Memorial East Texas and Centura Health do not require collateral postings. The fair value of the swaps is estimated based on the present value sum of anticipated future net cash settlements until the swaps' maturities. Cash collateral balances are netted against the fair value of the swaps, and the net amount is reflected in other liabilities in the accompanying consolidated balance sheets. At December 31, 2018, the net swap liability reflected in other liabilities was \$40.2 million, net of swap collateral posted of \$176.8 million. The swap agreements, excluding the Centura Health swap, are secured by Obligations issued under the COD. (See Note 8 in the Consolidated Interim Financial Statements (unaudited) as of December 31, 2018 and 2017.)

		Outstanding Notional	
Obligated Party	Туре	December 31, 2018	<b>Termination Date</b>
CHI <sup>1</sup>	Total Return	\$72.0	4/10/2019 -1/16/2020
СНІ	Fixed Payer	150.9	5/1/2025
CHI	Fixed Payer	217.8	3/1/2032
CHI	Fixed Payer	96.6	9/1/2036
CHI	Fixed Payer	125.6	9/1/ 2036
CHI	Fixed Payer	19.3	9/1/2036
CHI	Fixed Payer	98.3	12/1/2036
CHI	Fixed Payer	147.5	12/1/2036
CHI St. Luke's	Fixed Payer	119.0	2/18/2031
CHI St. Luke's	Fixed Payer	92.5	2/15/2032
CHI St. Luke's	Fixed Payer	100.0	2/15/2047
CHI St. Luke's	Fixed Payer	100.0	2/15/2047
Centura Health <sup>2</sup>	Fixed Payer	14.3	5/20/2024
Madonna Manor	Total Return	27.0	8/15/2020
Memorial East Texas	Fixed Payer	24.0	2/15/2035
Memorial East Texas	Fixed Payer	16.8	2/15/2028
St. Joseph Regional Health <sup>3</sup>	Total Return	49.8	8/15/2020
St. Joseph Regional Health	Fixed Payer	45.2	1/1/2028
St. Joseph Regional Health	Basis	<u>30.0</u>	3/1/2028
Total Notional Amount		<u>\$ 1,546.7</u>	

<sup>&</sup>lt;sup>1</sup> Represents 13 Total Return Swaps.

<sup>&</sup>lt;sup>2</sup> Not secured by CHI COD obligations.

<sup>&</sup>lt;sup>3</sup> Represents 4 Total Return Swaps.

# 5. LIQUIDITY AND CAPITAL RESOURCES

### **Cash Equivalents and Internally Designated Investments**

CHI holds highly liquid investments to enhance its ability to satisfy liquidity needs. Asset allocations are reviewed monthly and compared to investment allocation targets included within CHI's investment policy. At December 31, 2018 and June 30, 2018, CHI had cash and equivalents and internally designated investments (including net unrealized gains and losses) as described in the table below.

(\$ in thousands)	December 31, 2018	June 30, 2018
Cash and equivalents	\$871,505	\$510,456
Internally designated investments	<u>4,585,986</u>	<u>5,308,868</u>
Total	\$5,457,49 <u>1</u>	\$5,819,32 <b>4</b>

CHI maintains an Operating Investment Program (the "Program") administered by the Corporation. The Program is structured as a limited partnership with the Corporation as the managing general partner.

The Program contracts with investment advisers to manage the investments within the Program. Substantially all CHI long-term investments are held in the Program. The Corporation requires all Participants to invest in the Program. The Program consists of equity securities, fixed-income securities and alternative investments (e.g., private equity, hedge funds and real estate interests). The asset allocation is established by the Finance Committee of the Board of Stewardship Trustees. At December 31, 2018, the target asset allocation for the Program's Long-Term Pool was 47% equity securities, 31% fixed-income securities, 22% alternative investments, and 0% cash and equivalents. Alternative investments within the Program have limited liquidity. As of December 31, 2018, illiquid investments not available for redemption totaled \$400.7 million, and investments available for redemption within 180 days at the request of the Program totaled \$889.3 million. The asset allocation for the Program's Intermediate Pool was 100% fixed-income securities. As of December 31, 2018, 91.9% of the Program's assets were invested in the Long-Term Pool, with 8.1% of assets invested in the Intermediate Pool. The Program's return was (3.4)% for the six months ended December 31, 2018.

#### LIQUIDITY ARRANGEMENTS

The Corporation maintains several liquidity facilities that are dedicated to funding optional or mandatory tenders of its variable rate debt and paying the maturing principal of the commercial paper notes in the event remarketing proceeds are unavailable for such purpose. At December 31, 2018, no amounts were drawn on these lines. The Corporation's dedicated self-liquidity lines are set forth below and can be found at <a href="http://emma.msrb.org">http://emma.msrb.org</a>.

### CHI Dedicated Self-Liquidity Lines – December 31, 2018

Bank (\$ in millions)	Committed Amount	Expiration
Northern Trust	\$65.0	6/28/2019
PNC Bank	125.0	8/23/2019
MUFG Union Bank	125.0	9/27/2019
J.P. Morgan	50.0	9/30/2019
BNY Mellon	<u>50.0</u>	12/13/2019
Total Self-Liquidity Lines	<u>\$365.0</u>	

# 6. LIQUIDITY REPORT

CHI posts a liquidity report monthly, which can be found at <a href="https://emma.msrb.org">www.dacbond.com</a> and <a href="https://emma.msrb.org">https://emma.msrb.org</a>.

# PART VI: LEGAL PROCEEDINGS

### PENDING LITIGATION/REGULATORY MATTERS

CHI operates in a highly litigious industry. As a result, various lawsuits, claims and regulatory proceedings have been instituted or asserted against it from time to time. CHI has knowledge of certain pending suits against certain of its entities that have arisen in the ordinary course of business. In the opinion of management, CHI maintains adequate insurance and/or other financial reserves to cover the estimated potential liability for damages in these cases, or, to the extent such liability is uninsured, adverse decisions will not have a material adverse effect on the financial position or operations of CHI.

General Observation Relating to Status as Health Care System. CHI, like all major health care systems, periodically may be subject to investigations or audits by federal, state and local agencies involving compliance with a variety of laws and regulations. These investigations seek to determine compliance with, among other things, laws and regulations relating to Medicare and Medicaid reimbursement, including billing practices for certain services. Violation of such laws could result in substantial monetary fines, civil and/or criminal penalties and exclusion from participation in Medicare, Medicaid or similar programs.

**St. Joseph–London.** St. Joseph London ("SJHS") is party to a corporate integrity agreement ("CIA") with the Office of Inspector General that imposes certain compliance oversight obligations solely at SJHS's facility following a 2014 settlement with the federal government, the Commonwealth of Kentucky and others to resolve civil and administrative monetary claims raised in a *qui tam* lawsuit relating to certain diagnostic and therapeutic cardiac procedures performed at SJHS's facility and the financial relationship with certain cardiac physicians and physician groups. The CIA expires in February 2019.

Numerous civil lawsuits were also filed against the Corporation and SJHS claiming damages for alleged unnecessary cardiac stent placements and other cardiac procedures. One such case, *Kevin Ray Wells, Sr. v. Catholic Health Initiatives, et. al.,* Case No. 12-CI-00090 remains unresolved. In August 2016, the jury in that matter found in favor of the plaintiff and awarded compensatory damages in an amount just under \$1.3 million and punitive damages of \$20.0 million. Post-trial motions were filed and, while the trial court did not set aside the verdict, it did reduce the punitive damage award to \$5.0 million. The rulings of the trial court were then appealed. Oral argument before a three-judge panel of the appellate court was held on July 13, 2018 in Louisville, Kentucky. On August 10, 2018, the appellate court unanimously and fully reversed the trial court judgment and remanded the case back to the lower court for a new trial. All damages were vacated. Plaintiff has filed a request for discretionary review with the Kentucky Supreme Court. The parties have submitted their briefs and are now awaiting a decision from the Kentucky Supreme Court. In an effort to bring finality to the matter while it is pending before the Kentucky Supreme Court, mediation has been set for Friday, March 8, 2019. Management believes that adequate reserves have been established and that the outcome of the current litigation will not have a material adverse effect on the financial position or results of operations of CHI.

**Washington State Attorney General Civil Litigation.** The Washington State Attorney General's office ("WA AG") filed two civil lawsuits in 2017.

In the first action, on August 31, 2017, the WA AG filed a civil lawsuit in the U.S. District Court for the Western District of Washington against Franciscan Health System ("FHS") and Franciscan Medical Group (collectively "CHI Franciscan Health"), and two physician practices, The Doctors Clinic ("TDC") and WestSound Orthopaedics, PS ("WSO"). The lawsuit seeks to unwind CHI Franciscan Health's 2016 transactions with TDC and WSO, claiming that

they resulted in increased prices and decreased competition for adult primary care and orthopedic physicians' services on Kitsap Peninsula in violation of federal antitrust laws and the Washington Consumer Protection Act, and further seeks monetary disgorgement, civil penalties and fees. The Court has denied both a motion to dismiss from CHI Franciscan Health and an early motion for summary judgment from the WA AG regarding the WA AG's claim that the agreement between CHI Franciscan Health and TDC constitutes *per se* illegal price-fixing, holding that that question cannot be resolved without a full factual record. Discovery has ended. CHI Franciscan Health has filed a motion for partial summary judgment, and the WA AG has filed a motion for partial judgment on the pleadings, both of which are pending. The parties have exchanged settlement offers but remain very far apart on the terms of any settlement. A trial date of March 19, 2019 has been set. No assurance can be given as to the timing or outcome of this litigation matter.

In the second action, on September 5, 2017, the WA AG filed a civil lawsuit in Pierce County Superior Court, Washington, against St. Joseph Medical Center ("SJMC") alleging that SJMC violated the Washington Consumer Protection Act by failing to comply with Washington State's charity care laws and regulations from 2012 to the present, allegedly resulting in a failure to provide charity care to patients who would have qualified for charity care assistance under state law and FHS's charity care policy. The lawsuit seeks civil money penalties, restitution to patients, attorneys' fees and other injunctive relief. FHS has filed an answer to this lawsuit and discovery is proceeding. A tentative trial date of July 15, 2019 has been set. FHS and the WA AG have recently engaged in mediation discussions, and FHS believes that the parties have made substantial progress towards achieving settlement and are in continued negotiations with the WA AG at this time. No assurance can be given as to the timing or outcome of this litigation matter.

Additionally, on June 22, 2018, an alleged former patient filed a purported class-action lawsuit against FHS and SJMC in the U.S. District Court for the Western District of Washington, alleging that SJMC violated the Washington Consumer Protection Act, breached the covenant of good faith and fair dealing, and were unjustly enriched, by failing to affirmatively screen her and other similarly situated patients who sought emergency care at SJMC for charity care before engaging in collection efforts, in violation of Washington's charity care laws and regulations. The lawsuit seeks treble damages, restitution, costs, attorneys' fees and injunctive relief. FHS and SJMC answered the complaint on July 19, 2018. The deadline for the plaintiffs to seek class certification is in November 2019. FHS' intention is to negotiate a global settlement of the disputes involving SJMC's historical charity care practices involving Washington State's claims as well as those in the purported class-action. No assurance can be given as to the timing or outcome of this litigation matter.

J.R. v. Blue Cross & Blue Shield of Illinois, et al., No. 2:18-cv-1191 (W.D. Wash.) The lead plaintiff in the referenced action is a minor child diagnosed with autism spectrum disorder (ASD) who is a beneficiary under the Catholic Health Initiatives (CHI) medical plan (the Plan). In a federal court complaint filed on August 14, 2018, plaintiff (by and through his parents) alleges that coverage for certain physician recommended ASD treatment was denied by the Plan's third-party administrator, Blue Cross & Blue Shield of Illinois, on the basis that the Plan excluded coverage for same. CHI and the Plan, along with the third-party administrator are named defendants in the litigation. Plaintiff alleges that exclusion of the therapy sought for ASD treatment is not at parity with the Plan's coverage of medical and surgical services and, as a result, fails to comply with the Federal Mental Health Parity and Addiction Equity Act (Parity Act). Plaintiff brings the action based on alleged violation of the Parity Act on behalf of himself and a putative class of similarly situated individuals/beneficiaries. The class has not yet been certified. Plaintiff seeks damages in an unspecified amount, injunctive relief, and other relief. Discovery is in the very early stages. Due to inherent uncertainties in matters of this type, no opinion as to the outcome can be provided at this time.

**Pharmacy Plus Investigation**. On November 15, 2017, KentuckyOne Health ("KOH") received a Civil Investigative Demand ("CID") from the United States Department of Justice ("DOJ"), seeking information and documents regarding a retail (Pharmacy Plus) and specialty (Pharmacy Plus Specialty) pharmacy (collectively, "Pharmacy Plus"), which are part of Jewish Hospital & St. Mary's HealthCare. Specifically, the DOJ has sought information about

Pharmacy Plus's: (i) compliance with Medicare Part B billing criteria for prescriptions; (ii) waiver or reduction of copayments or co-insurance amounts involving federal healthcare program beneficiaries; (iii) relationships with a certain physician group, and (iv) pricing and charge information for certain prescription drugs. KOH has begun providing information and documents in response to the CID. Due to inherent uncertainties in matters of this type, we express no opinion as to the potential outcome of this investigation.

# **APPENDIX A**

# CATHOLIC HEALTH INITIATIVES CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTAL INFORMATION

As of December 31, 2018 and for the three and six months ended December 31, 2018 and 2017

# CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

Catholic Health Initiatives As of December 31, 2018, and for the Three and Six Months Ended December 31, 2018 and 2017

### Consolidated Interim Financial Statements (Unaudited)

As of December 31, 2018, and for the Three and Six Months Ended December 31, 2018 and 2017

### **Contents**

Consolidated Interim Financial Statements (Unaudited)

Consolidated Balance Sheets (Unaudited)	J
Consolidated Statements of Operations (Unaudited)	3
Consolidated Statements of Changes in Net Assets (Unaudited)	
Consolidated Statements of Cash Flows (Unaudited)	
Notes to Consolidated Interim Financial Statements (Unaudited)	
totes to consolidated interim i maneral statements (characted)	•••

### Consolidated Balance Sheets

(In Thousands)

	-	2018	June 30, 2018			
	(L	Inaudited)				
Assets						
Current assets:	ф	051 505	ф	510.456		
Cash and equivalents	\$	871,505	\$	510,456		
Net patient accounts receivable, less allowances for bad debts						
of \$827,130 at June 30, 2018		2,164,406		2,121,582		
Other accounts receivable		270,419		257,285		
Current portion of investments and assets limited as to use		125,976		64,348		
Inventories		316,251		298,636		
Assets held for sale		189,422		195,698		
Prepaid and other		213,295		144,003		
Total current assets		4,151,274		3,592,008		
Investments and assets limited as to use:						
Internally designated for capital and other funds		4,585,986		5,308,868		
Held by trustees		74,412		76,080		
Held for insurance purposes		658,539		829,402		
Restricted by donors		264,431		258,513		
Total investments and assets limited as to use		5,583,368		6,472,863		
Property and equipment, net		7,994,466		8,110,767		
Investments in unconsolidated organizations		1,752,780		1,732,840		
Intangible assets and goodwill, net		417,231		421,388		
Notes receivable and other		251,397		265,441		
Total assets	\$	20,150,516	\$	20,595,307		

Continued on following page

# Consolidated Balance Sheets (continued) (In Thousands)

	<b>Decemb 2018</b> (Unaud)	<u> </u>	June 30, 2018
Liabilities and net assets	(Onana)	ucu)	
Current liabilities:			
Compensation and benefits	\$	<b>678,017</b> \$	568,986
Third-party liabilities, net	·	87,478	131,670
Accounts payable and accrued expenses	1,5	540,062	1,480,365
Liabilities held for sale		222,921	251,710
Variable-rate debt with self-liquidity		96,700	96,700
Commercial paper and current portion of debt	1,9	997,674	2,087,406
Total current liabilities		522,852	4,616,837
Pension liability	8	328,127	854,427
Self-insured reserves and claims		606,946	623,267
Other liabilities	9	98,080	1,027,091
Long-term debt	6,3	358,186	6,341,931
Total liabilities	13,4	414,191	13,463,553
Net assets:			
Net assets attributable to CHI	6,1	136,983	6,528,635
Net assets attributable to noncontrolling interests	2	289,216	300,428
Unrestricted	6,4	126,199	6,829,063
Temporarily restricted	2	211,976	207,695
Permanently restricted		98,150	94,996
Total net assets		736,325	7,131,754
Total liabilities and net assets	<b>\$</b> 20,1	<u>\$</u>	20,595,307

See accompanying notes.

# Consolidated Statements of Operations (In Thousands) (Unaudited)

	Three Months Ended December 31,		Six Months Ended December 31,			
		2018	2017	2018	2017	
Revenues:						
Net patient services revenues						
before provision for doubtful accounts			\$ 3,814,917	\$	7,505,725	
Provision for doubtful accounts		_	(207,240)		(403,238)	
Net patient services revenues	\$	3,636,232	3,607,677	\$ 7,163,986	7,102,487	
Other operating revenues:						
Donations		5,898	13,726	14,913	22,079	
Changes in equity of unconsolidated organizations		(5,061)	7,298	(1,537)	11,403	
Hospital ancillary revenues		94,741	85,629	179,046	169,920	
Other		101,456	103,643	205,248	207,853	
Total other operating revenues		197,034	210,296	397,670	411,255	
Total operating revenues		3,833,266	3,817,973	 7,561,656	7,513,742	
Expenses:						
Salaries and wages		1,535,900	1,535,190	3,019,478	3,024,922	
Employee benefits		286,848	282,276	564,383	558,531	
Purchased services, medical professional fees						
and consulting		587,034	577,593	1,171,080	1,139,103	
Supplies		634,312	622,142	1,246,574	1,218,579	
Utilities		46,201	47,288	95,370	99,063	
Rentals, leases, maintenance and insurance		245,229	204,503	468,182	427,027	
Depreciation and amortization		205,547	207,043	412,869	432,631	
Interest		82,153	76,249	163,095	151,359	
Other		246,664	250,897	509,490	511,451	
Total operating expenses before restructuring,				•		
impairment and other losses		3,869,888	3,803,181	7,650,521	7,562,666	
(Loss) income from operations before restructuring,						
impairment and other losses		(36,622)	14,792	(88,865)	(48,924)	
Restructuring, impairment and other losses		20,615	16,318	 41,816	30,488	
Loss from operations		(57,237)	(1,526)	(130,681)	(79,412)	
Nonoperating gains (losses):						
Investment (losses) gains, net		(330,689)	198,691	(192,358)	413,628	
Gains on early extinguishment of debt		_	_	_	208	
Realized and unrealized (losses) gains on interest rate swaps		(29,754)	12,307	(15,801)	8,325	
Other nonoperating (losses) gains		(2,370)	6,140	 (6,244)	8,208	
Total nonoperating (losses) gains		(362,813)	217,138	 (214,403)	430,369	
(Deficit) excess of revenues over expenses		(420,050)	215,612	(345,084)	350,957	
Excess of revenues over expenses attributable to noncontrolling interest		4,216	12,028	 8,420	16,248	
(Deficit) excess of revenues over expenses attributable to CHI	\$	(424,266)	\$ 203,584	\$ (353,504) \$	334,709	

See accompanying notes.

# Consolidated Statements of Changes in Net Assets (In Thousands)

	Attributable	Attributable to Noncontrolling Interests	Total	Temporarily Restricted Net	Permanently Restricted Net	Total Net
		C C C C C C C C C C C C C C C C C C C		C32 CC87	CHA CITY	C3.2.C3.7
Balances, July 1, 2017	\$ 7,047,905	\$ 367,483 \$	7,415,388	\$ 214,250	\$ 97,096	\$ 7,726,734
Excess of revenues over expenses	193,652	28,449	222,101	1	1	222,101
Net loss from discontinued operations	(790,493)	(3,261)	(793,754)	I	I	(793,754)
Change in pension funded status	139,204	4,360	143,564	I	I	143,564
Temporarily and permanently restricted contributions	I	I	I	41,883	563	42,446
Net assets released from restriction for capital	20,584	I	20,584	(20,584)	I	I
Net assets released from restriction for operations	I	I	I	(26,552)	I	(26,552)
Investment income	I	I	I	4,760	<i>L</i> 69	5,457
Distributions to noncontrolling owners	I	(33,384)	(33,384)	I	I	(33,384)
Noncontrolling ownership purchase	(91,483)	(63,968)	(155,451)	I	I	(155,451)
Other changes in net assets	9,266	749	10,015	(6,062)	(3,360)	593
Net decrease in net assets	(519,270)	(67,055)	(586,325)	(6,555)	(2,100)	(594,980)
Balances, June 30, 2018	6,528,635	300,428	6,829,063	207,695	94,996	7,131,754
(Deficit) excess of revenues over expenses	(353,504)	8,420	(345,084)	I	I	(345,084)
Net loss from discontinued operations	(36,541)	I	(36,541)	I	I	(36,541)
Temporarily and permanently restricted contributions	I	I	I	25,574	3,673	29,247
Net assets released from restriction for capital	7,827	I	7,827	(7,827)	I	I
Net assets released from restriction for operations	I	I	I	(9,838)	I	(9,838)
Investment income (loss)	45	I	45	(2,638)	(995)	(3,159)
Distributions to noncontrolling owners	I	(19,978)	(19,978)	I	I	(19,978)
Other changes in net assets	(9,479)	346	(9,133)	(066)	47	(10,076)
Net (decrease) increase in net assets	(391,652)	(11,212)	(402,864)	4,281	3,154	(395,429)
Balances. December 31, 2018 (unaudited)	\$ 6.136.983	\$ 289.216 \$	6.426.199	\$ 211.976	98 150	\$ 6.736.325

See accompanying notes.

### Consolidated Statements of Cash Flows

(In Thousands) (Unaudited)

Adjustments to reconcile (decrease) in net assets to net cash provided by operating activities:  Loss on deconsolidation of subsidiary  Purchase of noncontrolling interest  Depreciation and amortization  Provision for doubtful accounts  - 402	5,539) 9,167 9,000 2,631 3,238 1,403) 5,694) 2,466 2,005 (208) 3,315) 1,050)
Operating activities Decrease in net assets Adjustments to reconcile (decrease) in net assets to net cash provided by operating activities:  Loss on deconsolidation of subsidiary  Purchase of noncontrolling interest Depreciation and amortization Provision for doubtful accounts  \$ (395,429) \$ (450)  - 319  412,869  430  412,869  430	5,539) 9,167 9,000 2,631 3,238 1,403) 5,694) 2,466 2,005 (208) 3,315)
Decrease in net assets Adjustments to reconcile (decrease) in net assets to net cash provided by operating activities:  Loss on deconsolidation of subsidiary  Purchase of noncontrolling interest Depreciation and amortization Provision for doubtful accounts  \$ (395,429) \$ (450)  - 319  412,869  430  412,869  430	0,167 0,000 2,631 3,238 1,403) 5,694) 2,466 2,005 (208) 3,315)
Adjustments to reconcile (decrease) in net assets to net cash provided by operating activities:  Loss on deconsolidation of subsidiary  Purchase of noncontrolling interest  Depreciation and amortization  Provision for doubtful accounts  - 402	0,000 2,631 3,238 1,403) 5,694) 2,466 2,005 (208) 3,315)
Loss on deconsolidation of subsidiary – 319 Purchase of noncontrolling interest – 150 Depreciation and amortization 412,869 Provision for doubtful accounts – 400	0,000 2,631 3,238 1,403) 5,694) 2,466 2,005 (208) 3,315)
Purchase of noncontrolling interest – 150 Depreciation and amortization 412,869 430 Provision for doubtful accounts – 400	2,631 3,238 1,403) 5,694) 2,466 2,005 (208) 3,315)
Depreciation and amortization 412,869 432 Provision for doubtful accounts - 402	3,238 1,403) 5,694) 2,466 2,005 (208) 3,315)
Provision for doubtful accounts – 403	3,238 1,403) 5,694) 2,466 2,005 (208) 3,315)
	1,403) 5,694) 2,466 2,005 (208) 3,315)
	5,694) 2,466 2,005 (208) 3,315)
	2,466 2,005 (208) 3,315)
	2,005 (208) 3,315)
	(208) 3,315)
Gains on early extinguishment of debt	3,315)
·	
	,,,,,,,
	5,145)
Net changes in current assets and liabilities:	,1 .0)
· · · · · · · · · · · · · · · · · · ·	2,837)
	3,927)
	9,410)
	5,168)
Net cash (used in) provided by operating activities, before net change	,,100)
	3,811
· / /	7,139
	),950
,	,,,,,,,
Investing activities  (287 522)	. 004)
	5,804)
	9,761)
Business acquisitions, net of cash acquired (8,298)	- 200
,	1,308
· · · · · · · · · · · · · · · · · · ·	5,856
	9,140)
	3,014
	.,321)
Financing activities	
· <b>/</b> · · ·	9,281
	7,945)
1	3,686
	7,410)
	),000)
Net cash used in financing activities (96,551) (22)	7,388)
Increase (decrease) in cash and equivalents 361,049 (11'	7,965)
Cash and equivalents at beginning of period 510,456 810	),235
Cash and equivalents at end of period \$871,505 \$ 69.	2,270

See accompanying notes.

Six Months Ended

### Notes to Consolidated Interim Financial Statements (Unaudited)

December 31, 2018

### 1. Summary of Significant Accounting Policies

### **Organization**

Catholic Health Initiatives (CHI), established in 1996, is a tax-exempt Colorado corporation and has been granted an exemption from federal income tax under Section 501(c)(3) of the Internal Revenue Code. CHI sponsors market-based organizations (MBO) and other facilities operating in 18 states, comprised of facilities and services that span the inpatient and outpatient continuum of care, including hospitals and clinics, academic health centers, major teaching hospitals, and critical access facilities; as well as community health service organizations, accredited nursing colleges, home health agencies, and living communities. CHI also has an offshore captive insurance company, First Initiatives Insurance, Ltd. (FIIL).

The mission of CHI is to nurture the healing ministry of the Church, supported by education and research. Fidelity to the Gospel urges CHI to emphasize human dignity and social justice as CHI creates healthier communities.

### **Basis of Presentation**

The consolidated interim financial statements of CHI as of December 31, 2018, and for the three and six months ended December 31, 2018 and 2017, reflect normal recurring adjustments, which in the opinion of management are necessary to fairly state its financial position, results of operations and cash flows for the periods presented. The consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim reporting, and accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. GAAP. However, CHI believes that the disclosures are adequate to make the information presented not misleading. These consolidated interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended June 30, 2018.

The preparation of financial statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results could vary from the estimates. Operating results for the three and six months ended December 31, 2018 and 2017, are not necessarily indicative of the results that may be expected for any future period or for a full fiscal year as revenues, expenses, assets and liabilities can vary during each quarter of the year.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

### **Principles of Consolidation**

CHI consolidates all direct affiliates in which it has sole corporate membership or ownership (Direct Affiliates) and all entities in which it has greater than 50% equity interest with commensurate control. All significant intercompany accounts and transactions are eliminated in consolidation.

### **Fair Value of Financial Instruments**

Financial instruments consist primarily of cash and equivalents, patient accounts receivable, investments and assets limited as to use, notes receivable and accounts payable. The carrying amounts reported in the consolidated balance sheets for these items, other than investments and assets limited as to use, approximate fair value. See Note 7, *Fair Value of Assets and Liabilities*, for a discussion of the fair value of investments and assets limited as to use.

### **Cash and Equivalents**

Cash and equivalents include all deposits with banks and investments in interest-bearing securities with maturity dates of 90 days or less from the date of purchase. In addition, cash and equivalents include deposits in short-term funds held by professional managers. The funds generally invest in high-quality, short-term debt securities, including U.S. government securities, securities issued by domestic and foreign banks, such as certificates of deposit and bankers' acceptances, repurchase agreements, asset-backed securities, high-grade commercial paper, and corporate short-term obligations.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

### **Net Patient Accounts Receivable and Net Patient Services Revenues**

On July 1, 2018, CHI adopted Accounting Standards Update 2014-09, *Revenue from Contracts with Customers (Topic 606)*, and subsequent amendments thereto (collectively referred to herein as Accounting Standards Codification (ASC) 606). The core principle of the new revenue recognition model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. ASC 606 also requires expanded disclosures regarding an entity's revenue recognition policies and significant judgments employed in the determination of revenue – see Note 5, *Net Patient Services Revenues*.

CHI adopted ASC 606 using a modified retrospective method of application to all contracts existing on July 1, 2018. CHI applied the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that net patient services revenues for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis.

The adoption of ASC 606 resulted in changes to the presentation for revenue related to uninsured or underinsured patients. Prior to the adoption of ASC 606, a significant portion of CHI's provision for doubtful accounts related to self-pay patients as well as co-payments and deductibles owed by patients with insurance. Under ASC 606, the estimated uncollectible amounts due from these patients are generally considered implicit price concessions, which are recorded as a direct reduction of net patient services revenues rather than as a provision for doubtful accounts. For the three and six months ended December 31, 2018, CHI recorded \$239.3 million and \$473.2 million, respectively, of implicit price concessions as a direct reduction of net patient services revenues that would have been recorded as provision for doubtful accounts prior to the adoption of ASC 606. For periods prior to the adoption of ASC 606, the provision for doubtful accounts was presented separately as a component of patient services revenues, consistent with the previous revenue recognition guidance. Additionally, at December 31, 2018, CHI recorded \$861.2 million as a direct reduction of net patient accounts receivable that would have been reflected as allowance for bad debts prior to the adoption of ASC 606. Other than these changes in presentation, the adoption of ASC 606 did not have a material impact on the consolidated balance sheet as of December 31, 2018, the consolidated statement of operations for the three and six months ended December 31, 2018, and the consolidated statement of changes in net assets for the six months ended December 31, 2018.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

Net patient accounts receivable has been adjusted to the estimated amounts expected to be collected. These estimated amounts are subject to further adjustments upon review by third-party payors – see Note 5, *Net Patient Services Revenues*.

### **Investments and Assets Limited as to Use**

Investments and assets limited as to use include assets set aside by CHI for future long-term purposes, including capital improvements and self-insurance. In addition, assets limited as to use include amounts held by trustees under bond indenture agreements, amounts contributed by donors with stipulated restrictions and amounts held for Mission and Ministry programs.

CHI has designated its investment portfolio as trading as the portfolio is actively managed to achieve investment returns. Accordingly, unrealized gains and losses on marketable securities are reported within excess of revenues over expenses. In addition, cash flows from the purchases and sales of marketable securities are reported as a component of operating activities in the accompanying consolidated statements of cash flows.

Direct investments in equity securities with readily determinable fair values and all direct investments in debt securities have been measured at fair value in the accompanying consolidated balance sheets. Investment income or loss (including realized gains and losses on investments, interest and dividends) is included in excess of revenues over expenses unless the income or loss is restricted by donor or law.

Investments in limited partnerships and limited liability companies are recorded using the equity method of accounting (which approximates fair value as determined by the net asset values of the related unitized interests) with the related changes in value in earnings reported as investment income or loss in the accompanying consolidated financial statements.

### **Inventories**

Inventories, primarily consisting of pharmacy drugs, and medical and surgical supplies, are stated at lower of cost (first-in, first-out method) or net realizable value.

### **Assets and Liabilities Held for Sale**

Assets and liabilities held for sale represent assets and liabilities that are expected to be sold within one year. A group of assets and liabilities expected to be sold within one year is classified as held

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

for sale if it meets certain criteria. The assets and liabilities held for sale are measured at the lower of carrying value or fair value less costs to sell. Such valuations include estimates of fair values generally based upon firm offers, discounted cash flows and incremental direct costs to transact a sale (Level 2 and Level 3 inputs).

### **Property and Equipment**

Property and equipment are stated at historical cost or, if donated or impaired, at fair value at the date of receipt or impairment. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed using the straight-line method. Buildings and improvements are depreciated over estimated useful lives of 5 to 84 years, equipment over 3 to 30 years, and land improvements over 2 to 25 years. For property and equipment under capital lease, amortization is determined over the shorter period of the lease term or the estimated useful life of the property and equipment.

Interest cost incurred during the period of construction of major capital projects is capitalized as a component of the cost of acquiring those assets. Capitalized interest of \$3.6 million and \$1.9 million was recorded in the three months ended December 31, 2018 and 2017, respectively, and \$6.3 million and \$4.1 million was recorded in the six months ended December 31, 2018 and 2017, respectively.

Costs incurred in the development and installation of internal-use software are expensed if they are incurred in the preliminary project stage or post-implementation stage, while certain costs are capitalized if incurred during the application development stage. Internal-use software is amortized over its expected useful life, generally between 2 and 15 years, with amortization beginning when the project is completed and the software is placed in service.

### **Investments in Unconsolidated Organizations**

Investments in unconsolidated organizations are accounted for under the cost or equity method of accounting, as appropriate, based on the relative percentage of ownership or degree of influence over that organization. The income or loss on the equity method investments is recorded in the consolidated statements of operations as changes in equity of unconsolidated organizations.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

### **Intangible Assets and Goodwill**

Intangible assets are comprised primarily of trade names, which are amortized over the estimated useful lives ranging from 10 to 25 years using the straight-line method. The weighted average useful life of the trade names is 16 years. Amortization expense of \$2.3 million and \$2.1 million was recorded in the three months ended December 31, 2018 and 2017, respectively, and \$4.6 million and \$4.4 million was recorded in the six months ended December 31, 2018 and 2017, respectively.

Goodwill is not amortized but is subject to annual impairment tests during the third quarter of the fiscal year, as well as more frequent reviews whenever circumstances indicate a possible impairment may exist; no such circumstances were identified at December 31, 2018. Impairment testing of goodwill is performed at the reporting unit level by comparing the fair value of the reporting unit's net assets against the carrying value of the reporting unit's net assets, including goodwill. Each MBO is defined as a reporting unit for purposes of impairment testing. The fair value of the reporting unit's net assets is generally estimated based on quantitative analysis of discounted cash flows (Level 3 measurement). The fair value of goodwill is determined by assigning fair values to assets and liabilities, with the remaining fair value reported as the implied fair value of goodwill.

The changes in the carrying amount of goodwill and intangibles is as follows as of the beginning of each fiscal period presented (in thousands):

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

	De	June 30, 2018		
Intangible assets, beginning of period	\$	233,285	\$	236,034
Acquisitions		(7(0)		1,084
Sales and other adjustments		(769)		(3,833)
Intangible assets, end of period		232,516		233,285
Accumulated amortization, beginning of period		(51,588)		(47,370)
Intangible amortization expense		(4,584)		(9,477)
Sales and other adjustments		491		5,259
Accumulated amortization, end of period		(55,681)		(51,588)
Intangible assets, net		176,835		181,697
Goodwill, beginning of period		239,691		231,995
Acquisitions		-		11,459
Impairments and other adjustments		705		(3,763)
Goodwill, end of period		240,396		239,691
Total intangible assets and goodwill, net	\$	417,231	\$	421,388

### **Notes Receivable and Other Assets**

Other assets consist primarily of notes receivable, pledges receivable, deferred compensation assets, long-term prepaid service contracts, deposits and other long-term assets. A summary of notes receivable and other assets is as follows (in thousands):

	De	cember 31,	June 30,
		2018	2018
Notes receivable:			
From related entities	\$	14,737	\$ 16,842
Other		36,364	35,566
Long-term pledge receivables		38,303	36,387
Reinsurance recoverable on unpaid losses and loss			
adjustment expense		37,220	39,772
Deferred compensation assets		71,079	75,199
Other long-term assets		53,694	61,675
Total notes receivable and other	\$	251,397	\$ 265,441

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

### **Net Assets**

Temporarily restricted net assets are those whose use has been limited by donors to a specific time period or purpose. Permanently restricted net assets consist of gifts with corpus values that have been restricted by donors to be maintained in perpetuity, including endowment funds. Temporarily restricted net assets and earnings on permanently restricted net assets, including earnings on endowment funds, are used in accordance with the donor's wishes primarily to purchase equipment, to provide charity care, and to provide other health and educational programs and services.

Unconditional promises to receive cash and other assets are defined as voluntary, nonreciprocal transactions between CHI and external parties, which are reported at fair value at the date the promise is received. Conditional promises and indications of donors' conditional intentions to give are defined as agreements where a barrier exists that must be overcome before CHI is entitled to the assets transferred or promised, or where a right of return of the transferred asset or a right of release of the promisor from its obligation to transfer the asset to CHI exists. Indicators of a gift containing a barrier are as follows: a requirement that a recipient's entitlement to transferred assets is contingent upon the achievement of a certain level of service, an identified number of units of output, or a specific outcome; the extent to which a stipulation limits discretion by the recipient on

the conduct of an activity; and whether a stipulation is related to the purpose of the agreement. The funds are reported at fair value at the date the barriers are overcome. All unrestricted contributions are reported as donation revenues in the accompanying consolidated statements of operations. All other gifts are reported as either temporarily or permanently restricted if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified as donations revenue when restricted for operations or as unrestricted net assets when restricted for property and equipment.

### **Performance Indicator**

The performance indicator is the excess of revenues over expenses, which includes all changes in unrestricted net assets other than changes in the pension liability funded status, net assets released from restrictions for property acquisitions, cumulative effect of changes in accounting principles, discontinued operations, contributions of property and equipment, and other changes not required to be included within the performance indicator under U.S. GAAP.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

### **Operating and Nonoperating Activities**

CHI's primary mission is to meet the health care needs in its market areas through a broad range of general and specialized health care services, including inpatient acute care, outpatient services, physician services, long-term care, and other health care services. Activities directly associated with the furtherance of this purpose are considered to be operating activities. Other activities that result in gains or losses peripheral to CHI's primary mission are considered to be nonoperating. Nonoperating activities include investment earnings, gains/losses from extinguishment of debt, net interest cost and changes in fair value of interest rate swaps, and the nonoperating component of Joint Operating Agreement (JOA) income share adjustments. Any infrequent and nonreciprocal contribution that CHI makes to enter a new market community or to expand upon existing affiliations is also classified as nonoperating.

### **Other Operating Revenues**

Other operating revenues include services sold to external health care providers, gains on acquisitions of subsidiaries, cafeteria sales, rental income, retail pharmacy and durable medical equipment sales, auxiliary and gift shop revenues, gains and losses on asset disposals, the operating component of JOA revenue share adjustments, premium revenues, and revenues from other miscellaneous sources.

### **Derivative and Hedging Instruments**

CHI uses derivative financial instruments (interest rate swaps) in managing its capital costs. These interest rate swaps are recognized at fair value on the consolidated balance sheets. CHI has not designated its interest rate swaps related to CHI's long-term debt as hedges. The net interest cost and change in the fair value of such interest rate swaps is recognized as a component of nonoperating gains (losses) in the accompanying consolidated statements of operations. It is CHI's policy to net the value of collateral on deposit with counterparties against the fair value of its interest rate swaps in other liabilities on the consolidated balance sheets.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

### **Functional Expenses**

CHI provides healthcare services, including inpatient, outpatient, ambulatory, long-term care and community-based services to individuals within the various geographic areas supported by its facilities. Support services include administration, finance and accounting, information technology, public relations, human resources, legal, mission services, and other functions that are supported centrally for all of CHI. Support services expenses as a percentage of total operating expenses were approximately 5.7% and 5.5% for the three months ended December 31, 2018 and 2017, respectively, and 5.7% and 5.4% for the six months ended December 31, 2018 and 2017, respectively.

### Restructuring, Impairment, and Other Losses

Restructuring, impairment, and other losses include charges relating to changes in business operations, severance costs, EPIC go-live support costs, goodwill and long-lived asset impairments, acquisition-related costs, and pension settlement activity. Changes in business operations include costs incurred periodically to implement reorganization efforts within specific operations, in order to align CHI's operations in the most strategic and cost-effective manner.

Details of CHI's restructuring, impairment and other losses are as follows (in thousands):

	Three Months Ended December 31,			S	ix Month Decemb			
	20	)18		2017	2	2018		2017
Changes in business operations	\$	15,867	\$	10,467	\$	32,796	\$	18,406
Severance costs		2,130		3,590		5,723		9,615
Impairment charges		2,618		2,261		3,297		2,467
Restructuring, impairment and other losses from continuing operations	\$	20,615	\$	16,318	\$	41,816	\$	30,488
Restructuring, impairment and other losses from discontinued operations	\$	3,760	\$	280,261	\$	16,026	\$	602,120

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 1. Summary of Significant Accounting Policies (continued)

Noncash impairment charges included in the consolidated statements of operations totaled \$2.6 million and \$2.3 million for the three months ended December 31, 2018 and 2017, respectively, and \$3.3 million and \$2.5 million for the six months ended December 31, 2018 and 2017, respectively. Discontinued operations are reported in the consolidated statements of changes in net assets. For the six months ended December 31, 2017, the discontinued operations include the loss on deconsolidation of University Medical Center (UMC), a subsidiary of CHI – see Note 4, Discontinued Operations, and Assets and Liabilities Held for Sale.

### **Income Taxes**

CHI is a tax-exempt Colorado corporation and has been granted an exemption from federal income tax under Section 501(c)(3) of the Internal Revenue Code. CHI owns certain taxable subsidiaries and engages in certain activities that are unrelated to its exempt purpose and therefore subject to income tax.

On December 22, 2017, the Tax Cuts and Jobs Act (the Tax Act) was enacted. The Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, creates new taxes on certain foreign sourced earnings, provides for a new excise tax on certain compensation of exempt organizations over \$1 million, and requires the separate calculation of unrelated business taxable income for each trade or business carried on.

Management reviews its tax positions annually and has determined that there are no material uncertain tax positions that require recognition in the accompanying consolidated financial statements.

### **Use of Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results could vary from the estimates.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 2. Joint Operating Agreements and Investments in Unconsolidated Organizations

### **Joint Operating Agreements**

CHI participates in JOAs with hospital-based organizations in three separate market areas. The agreements generally provide for, among other things, joint management of the combined operations of the local facilities included in the JOAs through Joint Operating Companies (JOC). CHI retains ownership of the assets, liabilities, equity, revenues and expenses of the CHI facilities that participate in the JOAs. The financial statements of the CHI facilities managed under all JOAs are included in the CHI consolidated financial statements. Transfers of assets from facilities owned by the JOA participants generally are restricted under the terms of the agreements.

As of December 31, 2018, and June 30, 2018, CHI has investment interests of 65%, 50%, and 50% in JOCs based in Colorado, Iowa, and Ohio, respectively. CHI's interests in the JOCs are included in investments in unconsolidated organizations and totaled \$462.7 million and \$435.8 million at December 31, 2018, and June 30, 2018, respectively. CHI recognizes its investment in all JOCs under the equity method of accounting. The JOCs provide varying levels of services to the related JOA sponsors, and operating expenses of the JOCs are allocated to each sponsoring organization.

### **Investments in Unconsolidated Organizations**

CHI holds noncontrolling interests in various organizations, accounted for under the cost or equity method of accounting, as appropriate. Significant investments are described below.

Conifer Health Solutions (Conifer) – As of December 31, 2018, and June 30, 2018, CHI holds a 23.8% equity method investment in Conifer totaling \$693.6 million and \$670.6 million, respectively. The investment in Conifer was acquired as part of a multi-year agreement with Conifer where Conifer provides revenue cycle services and health information management solutions for CHI acute care operations. Since CHI was granted incremental shares in Conifer in conjunction with the multi-year agreement with Conifer, CHI also has a deferred income balance related to the Conifer agreement of \$389.3 million and \$403.2 million as of December 31, 2018, and June 30, 2018, respectively, reported in other liabilities on the accompanying consolidated balance sheets. The deferred income balance is being amortized straight line over the remaining agreement term expiring in January 2033, offsetting revenue cycle services fees paid to Conifer, which are reported in purchased services expense in the accompanying consolidated statements of operations.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

## 2. Joint Operating Agreements and Investments in Unconsolidated Organizations (continued)

As a result of CHI recording its incremental equity ownership in Conifer at fair value, the carrying value of its equity method investment in Conifer was \$239.3 million and \$243.9 million greater than CHI's equity interest in the underlying net assets of Conifer as of December 31, 2018 and June 30, 2018, respectively, due to basis differences in the carrying amounts of the tangible and intangible assets of \$172.6 million and \$177.2 million, respectively, and of goodwill of \$66.7 million in both periods. Goodwill is not amortized but is subject to annual impairment tests during the third quarter of the fiscal year, as well as more frequent reviews whenever circumstances indicate a possible impairment may exist. No impairment of goodwill was identified as of December 31, 2018 and June 30, 2018. The basis differences of the tangible and intangible assets are being amortized over the average useful lives of the underlying assets, ranging from 8 to 25 years, as a reduction of CHI's equity earnings in Conifer.

**Premier Health Partners** (**Premier**) – Effective on January 1, 2018, CHI entered into an agreement with Premier, an Ohio nonprofit corporation operating various hospitals in southwest Ohio, to reorganize and restructure the existing JOA with Premier. The agreement provided that CHI transfer ownership of the Good Samaritan-Dayton MBO to Premier in exchange for a 22% interest in Premier. CHI's 22% equity method investment in Premier totaled \$293.1 million and \$310.8 million at December 31, 2018, and June 30, 2018, respectively.

### 3. Acquisitions, Affiliations, and Divestitures

There were no significant business combinations and affiliations, individually or in the aggregate, during the six months ended December 31, 2018 and 2017.

**KentuckyOne Health Noncontrolling Interest** – Effective September 1, 2017, CHI became the sole owner of KentuckyOne Health through the purchase of the noncontrolling interest from the remaining partner for \$150.0 million in cash consideration.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 4. Discontinued Operations, and Assets and Liabilities Held for Sale

The operations of Jewish Hospital and St. Mary's Healthcare, Inc. System (JHSMH) and QualChoice Health, Inc. (QualChoice Health) are reflected as discontinued operations, with their respective assets and liabilities reflected as held for sale, in accordance with ASC 205-20, *Presentation of Financial Statements – Discontinued Operations*.

**JHSMH Held for Sale** – In May 2017, CHI approved a plan to sell or otherwise dispose of certain entities of JHSMH. In fiscal year 2018, CHI entered into a non-binding letter of intent for the purchase of JHSMH and anticipates closing on a sale during fiscal year 2019. The assets and liabilities of JHSMH are valued at the lower of their carrying value or their fair value less cost to sell.

Additionally, in December 2018, CHI entered into a further non-binding proposal letter to negotiate a definitive agreement for the sale of the JHSMH acute care operations.

**QualChoice Health Held for Sale** – In September 2018, CHI entered into an asset purchase agreement for the sale of its Medicare Advantage health insurance operations in the state of Washington, effective in January 2019. The purchase price is contingent upon future increases in the number of lives covered by the Medicare Advantage plans acquired, and upon maintaining a specified Centers for Medicare & Medicaid Services (CMS) Star Rating as published annually in October 2018 and 2019.

In December 2018, CHI entered into a definitive agreement for the sale of its commercial insurance operations in the state of Arkansas. The agreement is pending regulatory approvals and is expected to be finalized in the second half of fiscal year 2019.

**UMC Deconsolidation -** Effective on July 1, 2017, and in accordance with the agreement entered into in December 2016 between KentuckyOne Health and UMC, UMC took over the management of its assets and CHI ceased consolidating the UMC operations. The transaction resulted in a loss on deconsolidation of \$319.2 million for the six months ended December 31, 2017, reflected in discontinued operations in the consolidated statement of changes in net assets.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 4. Discontinued Operations, and Assets and Liabilities Held for Sale (continued)

A reconciliation of major classes of assets and liabilities held for sale is presented below (in thousands):

	December 31, 2018			June 30, 2018
Other accounts receivable	\$	40,182	\$	23,672
Inventory	4	16,205	4	16,797
Investments held for insurance purposes		114,380		126,899
Property and equipment, net		4,490		6,918
Other assets		11,474		14,523
Total major classes of assets of the discontinued		,		
operations held for sale		186,731		188,809
Other assets held for sale		2,691		6,889
Total assets held for sale	\$	189,422	\$	195,698
Compensation and benefits	\$	50,486	\$	42,167
Accounts payable and accrued expenses		43,430		66,260
Debt		8,119		8,856
Self-insured reserves and claims		82,600		91,094
Other liabilities		34,219		36,918
Total major classes of liabilities of the discontinued				
operations held for sale		218,854		245,295
Other liabilities held for sale		4,067		6,415
Total liabilities held for sale	\$	222,921	\$	251,710

The \$2.7 million and \$6.9 million of other assets classified as held for sale as of December 31, 2018, and June 30, 2018, respectively, represent real estate and other assets that are scheduled to be sold in fiscal year 2019, measured at the lower of their carrying amount or fair value less cost to sell.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 4. Discontinued Operations, and Assets and Liabilities of Held for Sale (continued)

Operating results of discontinued operations are reported in the accompanying consolidated statements of changes in net assets, and are summarized as follows (in thousands):

	Three Months Ended December 31,			ŀ	Six Months Decembe			
		2018		2017		2018		2017
Net patient service revenues	\$	180,802	\$	181,275	\$	357,027	\$	360,707
Other operating revenues  Total operating revenues Salaries, wages and employee benefits		144,882 325,684 107,087		142,139 323,414 110,638		292,235 649,262 213,494		276,963 637,670 224,581
Purchased services and medical claims Depreciation and amortization		144,618 864		160,626 871		302,002 1,770		316,390 1,748
Other expenses  Total operating expenses before restructuring, impairment and other		76,413		73,658		153,130		146,936
losses Loss from operations before restructuring, impairment and other losses Restructuring, impairment and other losses		(3,298) (3,760)		345,793 (22,379) (280,261)		(21,134) (16,026)		689,655 (51,985) (602,120)
Loss from operations Nonoperating gains (losses)		(7,058) 1,706		(302,640) (55)		(37,160) 619		(654,105) 33
Deficit of revenues over expenses Deficit of revenues over expenses attributable to noncontrolling interest	\$ \$	. , ,	\$ \$	(302,695)	\$ \$	(36,541)	\$ \$	(654,072) (3,261)
Deficit of revenues over expenses attributable to CHI	\$	(5,352)	\$	(302,695)	\$	(36,541)		(650,811)

For the three and six months ended December 31, 2017, discontinued operations include the JHSMH impairment charge of \$272.0 million. For the six months ended December 31, 2017, restructuring, impairment and other losses from discontinued operations include the \$319.2 million loss on deconsolidation of UMC.

The discontinued operations reported \$2.5 million in capital expenditures for the three months ended December 31, 2017, and \$0.9 million and \$3.7 million for the six months ended December 31, 2018 and 2017, respectively.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### **5. Net Patient Services Revenues**

The performance obligation in CHI's patient contracts is to provide care to its patients and is generally satisfied over time for healthcare services in both the inpatient and outpatient setting, as patients simultaneously receive and consume the benefits provided as services are performed.

The performance obligation for inpatient acute care services is generally satisfied over an average of 4 to 5 days. CHI measures the period of time through which the performance obligation is satisfied from the time of the patient's admission into the hospital to the point when the patient no longer requires services, which is generally the time of discharge. Revenue for those patients receiving inpatient acute care services is recognized based on actual charges incurred in relation to total expected or actual charges. CHI believes this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs and outputs needed to satisfy the obligation.

The performance obligation for outpatient and physician services is generally satisfied over a period of less than one day.

Net patient services revenues are reported at the estimated transaction price from patients, third-party payors and others for services rendered, including estimated retroactive adjustments due to future audits, reviews and investigations. CHI's estimate of contractual adjustments and discounts was based on contractual agreements, discount policies and historical experience. The estimate of implicit price concessions was based on CHI's historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. There were no significant revenue reversals or impairment losses to report for the three and six months ended December 31, 2018.

Contractual Discounts and Third-Party Reimbursement – Net patient services revenues are derived from services provided to patients who are either directly responsible for payment or are covered by various insurance or managed care programs. CHI receives payments from the federal government on behalf of patients covered by the Medicare program, from state governments for Medicaid and other state-sponsored programs, from certain private insurance companies and managed care programs, and from patients themselves. A summary of payment arrangements with major third-party payors follows:

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### **5.** Net Patient Services Revenues (continued)

**Medicare** – Inpatient acute care and certain outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates per discharge or procedure. These rates vary according to patient classification systems based on clinical, diagnostic and other factors. Certain CHI facilities have been designated as critical access hospitals and, accordingly, are reimbursed their cost of providing services to Medicare beneficiaries. Professional services rendered by physicians are paid based on the Medicare allowable fee schedule.

**Medicaid** – Inpatient services rendered to Medicaid program beneficiaries are primarily paid under the traditional Medicaid plan at prospectively determined rates per discharge. Certain outpatient services are reimbursed based on a cost reimbursement methodology, fee schedules or discounts from established charges.

Other – CHI has also entered into payment agreements with certain managed care and commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis for payment to CHI under these agreements includes prospectively determined rates per discharge, discounts from established charges and prospectively determined daily rates.

Self-Pay – Consistent with CHI's mission, care is provided to patients regardless of their ability to pay. Therefore, CHI has determined that it has provided implicit price concessions to uninsured patients and patients with other uninsured balances such as co-payments and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts CHI expects to collect based on its collection history with those patients.

CHI estimates the transaction price for the patient portion and uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, implicit price concessions and charity.

Charity Care – As an integral part of its mission, CHI accepts and provides medically necessary health care to all patients without regard to the patient's financial ability to pay. Services to patients are classified as charity care in accordance with standards established across all MBOs. This amount is not included in net patient services revenue in the accompanying consolidated statements of operations and changes in net assets.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### **5.** Net Patient Services Revenues (continued)

Charity care represents services rendered for which partial or no payment is expected and includes the cost of providing services to persons who cannot afford health care due to inadequate resources and/or who are uninsured or underinsured. CHI determines the cost of charity care on the basis of an MBO's total cost as a percentage of total charges applied to the charges incurred by patients qualifying for charity care under CHI's policy. The estimated cost of charity care provided was \$58.8 million and \$57.0 million for the three months ended December 31, 2018 and 2017, respectively, and \$116.3 million and \$112.8 million for the six months ended December 31, 2018 and 2017, respectively, for continuing operations.

The composition of net patient services revenues by primary payor is summarized as follows (in thousands):

	Three Montl Decem	hs Ended ber 31,		ths Ended nber 31,
	2018	2017	2018	2017
Medicare	\$1,274,862	\$1,329,384	\$2,549,969	\$2,578,602
Medicaid	379,577	380,008	780,793	787,073
Managed care	1,630,256	1,546,023	3,071,976	2,975,357
Self-pay	57,359	43,512	109,951	75,705
Commercial and other	294,178	308,750	651,297	685,750
Total	\$3,636,232	\$3,607,677	\$7,163,986	\$7,102,487

Estimated Settlements - Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Included in third-party liabilities are estimated settlements related to Medicare and Medicaid of \$67.3 million and \$110.4 million at December 31, 2018, and June 30, 2018, respectively. Net patient services revenues from continuing operations increased by \$23.9 million and \$34.4 million for the three months ended December 31, 2018 and 2017, respectively, and by \$32.0 million and \$35.8 million for the six months ended December 31, 2018 and 2017, respectively, due to favorable changes in estimates related to prior-year settlements.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 6. Investments and Assets Limited as to Use

CHI's investments and assets limited as to use reported in the accompanying consolidated balance sheets are comprised of the following (in thousands):

	 December 31, 2018	June 30, 2018
Cash and equivalents	\$ 253,379	\$ 106,053
CHI Investment Program	4,810,538	5,534,127
Marketable equity securities	209,572	267,390
Marketable fixed-income securities	429,976	623,789
Hedge funds and other alternative investments	5,879	5,852
	 5,709,344	6,537,211
Less current portion	(125,976)	(64,348)
	\$ 5,583,368	\$ 6,472,863

CHI attempts to reduce its market risk by diversifying its investment portfolio using cash equivalents, fixed-income securities, marketable equity securities and alternative investments. Most of the U.S. Treasury, money market funds and corporate debt obligations as well as exchange-traded marketable securities held directly by CHI and by the CHI Investment Program (the Program) have an actively traded market. However, CHI also invests in commercial paper, mortgage-backed or other asset-backed securities, alternative investments (hedge funds, private equity investments, real estate funds, funds of funds, etc.), collateralized debt obligations, municipal securities and other investments that have potential complexities in valuation based upon the current conditions in the credit markets. For some of these instruments, evidence supporting the determination of fair value may not come from trading in active primary or secondary markets. Because these investments may not be readily marketable, the estimated value is subject to uncertainty and, therefore, may differ from the value that would have been used had an active market for such investments existed. Such differences could be material. However, management reviews the CHI investment portfolio on a regular basis and seeks guidance from its professional portfolio managers related to U.S. and global market conditions to determine the fair value of its investments. CHI believes the carrying amount of these financial instruments in the accompanying consolidated financial statements is a reasonable estimate of fair value.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### **6.** Investments and Assets Limited as to Use (continued)

The majority of all CHI long-term investments are held in the Program. The Program is structured under a Limited Partnership Agreement with CHI as managing general partner and numerous limited partners, most sponsored by CHI. The partnership provides a vehicle whereby virtually all entities associated with CHI, as well as certain other unrelated entities, can optimize investment returns while managing investment risk. Entities participating in the Program that are not consolidated in the accompanying financial statements have the ability to direct their invested amounts and liquidate and/or withdraw their interest without penalty as soon as practicable based on market conditions but within 180 days of notification. The Limited Partnership Agreement permits a simple-majority vote of the noncontrolling limited partners to terminate the partnership. Accordingly, CHI recognizes only the unitized portion of Program assets attributable to CHI and its Direct Affiliates. Program assets attributable to CHI and its Direct Affiliates represented 88% and 89%, respectively, of total Program assets at December 31, 2018 and June 30, 2018.

The Program asset allocation is as follows:

	December 31, 2018	June 30, 2018
Equity securities	38%	43%
Fixed-income securities	38	36
Alternative investments	23	20
Cash and equivalents	1	1
_	100%	100%

The CHI Finance Committee (the Committee) of the Board of Stewardship Trustees is responsible for determining target asset allocations among fixed-income, equity, and alternative investments. At least annually, the Committee reviews targeted allocations and, if necessary, makes adjustments to targeted asset allocations. Given the diversity of the underlying securities in which the Program invests, management does not believe there is a significant concentration of credit risk.

The Program allocation to alternative investments is based upon contractual commitment levels to various funds. These commitments are drawn by the fund managers as opportunities arise to invest the capital. As of December 31, 2018, the Program had committed to invest \$1.0 billion in 45 funds, of which \$886.8 million had been invested. The remaining \$117.2 million will be invested when, and if, requested by the funds. Alternative investments within the Program have limited liquidity. As of December 31, 2018, illiquid investments not available for redemption totaled \$400.7 million, and investments available for redemption within 180 days at the request of the Program totaled \$889.3 million.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### **6.** Investments and Assets Limited as to Use (continued)

Investment (losses) income, net are comprised of the following (in thousands):

	Three Months Ended December 31,			Six Months I December		
		2018	2017	2018	2017	
Dividend and interest income	\$	40,346 \$	37,935	\$ 73,353 \$	70,653	
Net realized gains		496	44,828	94,816	104,614	
Net unrealized (losses) gains		(371,531)	115,928	(360,527)	238,361	
Investment (losses) income, net from continuing operations		(330,689)	198,691	(192,358)	413,628	
Investment income (losses), net from						
discontinued operations		1,706	(54)	619	34	
Total investment (losses) income, net	\$	(328,983) \$	198,637	\$ (191,739) \$	413,662	

Direct expenses of the Program attributable to CHI and its Direct Affiliates for the prior fiscal year were approximately \$18.5 million, or 0.33% of total assets, for the entire fiscal year, reflected in investment gains. Direct expenses are estimated to remain at this level in the current fiscal year. Fees paid to certain alternative investment managers are not included in the Program's total expense calculation as they are not a direct expense of the Program, but the fees are deducted from the alternative investment's performance and reflected in investment gains.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 7. Fair Value of Assets and Liabilities

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820, *Fair Value Measurements and Disclosures*, establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 inputs) and the lowest priority to unobservable inputs (Level 3 inputs).

The three levels of the fair value hierarchy and a description of the valuation methodologies used for instruments measured at fair value are as follows:

Level 1 – Valuation is based upon quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 – Valuation is based upon quoted prices for similar assets and liabilities in active markets or other inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial asset or liability.

Level 3 – Valuation is based upon other unobservable inputs that are significant to the fair value measurement.

Certain of CHI's alternative investments are made through limited liability companies (LLC) and limited liability partnerships (LLP). These LLCs and LLPs provide CHI with a proportionate share of the investment gains (losses). CHI accounts for its ownership in the LLCs and LLPs under the equity method. CHI also accounts for its ownership in the Program under the equity method. As such, these investments are excluded from the scope of ASC 820.

Financial assets and liabilities measured at fair value on a recurring basis were determined using the market approach based upon the following inputs at December 31, 2018, and June 30, 2018 (in thousands):

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 7. Fair Value of Assets and Liabilities (continued)

	<b>December 31, 2018</b>								
	Fair Value Measurements at Reporting Date Using								
				(Level 1)		(Level 2)		(Level 3)	
			Qu	oted Prices		Other			
			j	in Active	(	Observable	Un	observable	
		Total		Markets		Inputs		Inputs	
Assets									
Assets limited as to use:									
Cash and short-term investments	\$	253,379	\$	177,107	\$	76,272	\$	_	
Equity securities		209,572		209,572		_		_	
Fixed-income securities		429,976		89,783		340,193		_	
Other investments		2,801		_		_		2,801	
Deferred compensation assets:									
Cash and short-term investments		4,386		4,386		_		_	
	\$	900,114	\$	480,848	\$	416,465	\$	2,801	
Liabilities									
Interest rate swaps	\$	216,948	\$	_	\$	216,948	\$	_	
Contingent consideration		79,825	-	_		_	-	79,825	
Deferred compensation liability		4,386		4,386		_			
•	\$	301.159	\$	4,386	\$	216,948	\$	79,825	

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 7. Fair Value of Assets and Liabilities (continued)

	June 30, 2018								
	Fair Value Measurements at Reporting Date Using								
				(Level 1)		(Level 2)		(Level 3)	
			Q	uoted Prices		Other		_	
				in Active		Observable	$\mathbf{U}_{1}$	nobservable	
		Total		Markets		Inputs		Inputs	
Assets									
Assets limited as to use:									
Cash and short-term investments	\$	106,053	\$	96,316	\$	9,737	\$	_	
Equity securities		267,390		267,390		_		_	
Fixed-income securities		623,789		185,307		438,482		_	
Other investments		2,585		_		_		2,585	
Deferred compensation assets:									
Cash and short-term investments		5,249		5,249		_		_	
	\$	1,005,066	\$	554,262	\$	448,219	\$	2,585	
Liabilities									
Interest rate swaps	\$	208,462	\$	_	\$	208,462	\$	_	
Contingent consideration	Ψ	80,891	Ψ	_	Ψ		Ψ	80,891	
Deferred compensation liability		5,249		5,249		_		_	
r	\$	294,602	\$	5,249	\$	208,462	\$	80,891	

The fair values of the securities included in Level 1 were determined through quoted market prices. Level 1 instruments include money market funds, mutual funds, and marketable debt and equity securities. The fair values of Level 2 instruments were determined through evaluated bid prices based on recent trading activity and other relevant information, including market interest rate curves and referenced credit spreads; estimated prepayment rates, where applicable, are used for valuation purposes and are provided by third-party services where quoted market values are not available. Level 2 instruments include corporate fixed-income securities, government bonds, mortgage and asset-backed securities, and interest rate swaps. The fair values of Level 3 securities are determined primarily through information obtained from the relevant counterparties for such investments. Information on which these securities' fair values are based is generally not readily available in the market. The fair value of the contingent consideration liability was determined based on estimated future cash flows and probability-weighted performance assumptions, discounted to net present value. The contingent consideration liability balance was adjusted to reflect \$4.0 million of payments made since June 30, 2018, and to reflect a \$3.0 million increase for changes in payment assumptions, reported in other expenses in the consolidated statements of operations.

### Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### 8. Debt Obligations

The following is a summary of debt obligations (in thousands):

	December 31, 201	8	June 30, 2018
Debt secured under the CHI COD			
Fixed-rate debt:			
Fixed-rate serial and term exempt bonds payable in installments from 2019	d 2 (02 F0F	ф	2 504 522
through 2045; interest at 2.84% to 7.0% Fixed-rate serial and term taxable bonds payable in installments from 2022	\$ 2,692,597	\$	2,784,522
through 2042; interest at 2.95% to 4.35%	1,515,000		1,790,000
Fixed-rate direct purchase exempt bonds subject to mandatory tender from 2021 through 2022;	1,010,000		1,770,000
interest set at 2.84% to 3.17%	54,980		_
Long-term rate exempt bonds subject to mandatory tender from 2019 through			
2021; interest at 1.88% to 5.5%	141,870		141,870
Total fixed-rate debt	4 404 447		4.717.202
Variable-rate debt	4,404,447		4,716,392
Floating rate notes subject to mandatory tender from 2020 through 2025; interest			
set at prevailing market rates (2.5% to 3.11% at December 31, 2018)	411,145		411,145
Variable-rate demand bonds subject to optional 7-day tender terms and mandatory	,		, -
tender from 2032 through 2035; interest set at prevailing market rates (1.85% to			
2.02% at December 31, 2018)	96,700		96,700
Variable-rate direct purchase exempt bonds subject to mandatory tender from 2019 through 2024;			
interest set at prevailing market rates (2.61% to 3.61% at December 31, 2018)	925,292		928,287
Variable-rate direct purchase taxable bonds subject to mandatory tender from 2019 through 2021;	923,292		920,207
interest set at prevailing market rates (3.72% to 4.1% at			
December 31, 2018)	925,000		650,000
Bank line of credit maturing July 2019; interest set at prevailing market rates			
(3.27% at December 31, 2018)	250,000		250,000
Commercial paper notes with maturities ranging 2 to 94 days from December 31, 2018; interest set	001 000		001.000
at prevailing market rates (3.07% at December 31, 2018)	881,000		881,000
Total variable-rate debt	3,489,137		3,217,132 7,933,524
Total debt secured under the CHI COD	7,893,584		7,933,324
St. Leonard Master Trust Indenture fixed-rate exempt bonds payable in installments			
through 2040; interest at 6.0% to 6.63%	39,575		39,707
Other debt:	,-		,
Capital lease obligations	107,505		112,889
Note payable issued to Episcopal Health Foundation payable in installments			
through 2020; interest at 4.0%	98,726		98,726
Other notes payable and debt obligations	318,641		345,467
Total debt obligations before unamortized debt issuance costs, debt premium and debt discount, net	8,458,031		8,530,313
Unamortized debt issuance costs, debt premium and debt discount, net	(5,471)		(4,276)
Total debt obligations	8,452,560		8,526,037
Less amounts classified as current:	0,102,000		-,,
Variable-rate debt with self-liquidity	(96,700)		(96,700)
Commercial paper and current portion of debt	(1,997,674)		(2,087,406)
Long-term debt	\$ 6,358,186	\$	6,341,931

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### **8. Debt Obligations (continued)**

CHI issues the majority of its debt under the Capital Obligation Document (COD) and is the sole obligor. Bondholder security resides both in the unsecured promise by CHI to pay its obligations and in its control of its Direct Affiliates. Covenants include a minimum CHI debt service coverage ratio and certain limitations on secured debt. The Direct Affiliates of CHI, defined as Participants under the COD, have agreed to certain covenants related to corporate existence, maintenance of insurance and exempt use of bond-financed facilities.

Debt issued under the St. Leonard Master Trust Indenture is secured by the property of St. Leonard in Centerville, Ohio, and a pledge of gross revenues.

### **Debt Redemptions and Reissuances**

In July 2018, CHI issued \$275.0 million of Series 2018A taxable bonds subject to mandatory tender in August 2021. Proceeds were used to fund the \$275.0 million Series 2013D taxable bonds principal payment due in August 2018. Additionally, in July 2018, CHI extended the mandatory purchase date of the \$250.0 million Series 2017A taxable bonds from August 2018 to July 2021. As a result, CHI classified the Series 2013D and Series 2017A taxable bonds as long-term debt as of June 30, 2018.

In August 2018, CHI issued \$200.0 million of Series 2018B taxable bonds subject to mandatory tender in August 2019. The proceeds were subsequently used to reimburse the funding of the \$200.0 million Series 2016 taxable bonds, which were subject to mandatory tender in September 2018.

### Liquidity Facilities, Credit Facilities, and Lines of Credit

CHI has external liquidity facilities available totaling \$365.0 million at December 31, 2018, and June 30, 2018, which can be used to support CHI's obligations to fund tenders of variable rate demand bonds and to pay maturing principal of commercial paper.

At December 31, 2018, and June 30, 2018, CHI classified as current \$881.0 million of commercial paper due to maturities of less than one year and \$96.7 million of variable rate demand bonds (VRDBs) due to the holder's ability to put such VRDBs back to CHI on a daily basis, after providing a seven-day notice to tender.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### **8. Debt Obligations (continued)**

At December 31, 2018, and June 30, 2018, CHI had a credit facility with a third-party bank totaling \$69.0 million, of which letters of credit totaling \$59.4 million and \$59.3 million at December 31, 2018 and June 30, 2018, respectively, have been designated for the benefit of third parties, principally in support of the self-insurance programs administered by FIIL. No amounts were outstanding under this credit facility at December 31, 2018 and June 30, 2018.

At December 31, 2018, and June 30, 2018, CHI had a \$250.0 million outstanding bank line of credit, which was fully drawn, and matures in July 2019.

### **Interest Rate Swap Agreements**

CHI utilizes various interest rate swap contracts to manage the risk of increased interest rates payable of certain variable-rate bonds. The fixed-payer swap agreements convert CHI's variable-rate debt to fixed-rate debt. Generally, it is CHI's policy that all counterparties have an AA rating or better. The swap agreements generally require CHI to provide collateral if CHI's liability, determined on a mark-to-market basis, exceeds a specified threshold that varies based upon the rating on CHI's long-term indebtedness.

The fair value of the swaps is estimated based on the present value sum of anticipated future net cash settlements until the swaps' maturities. Cash collateral balances are netted against the fair value of the swaps, and the net amount is reflected in other liabilities in the accompanying consolidated balance sheets. At December 31, 2018, and June 30, 2018, the net swap liability reflected in other liabilities was \$40.2 million and \$33.6 million, respectively, net of swap collateral posted of \$176.8 million and \$174.9 million, respectively. The change in the fair value of swap agreements resulted in a net (loss) gain of \$(25.7) million and \$19.8 million for the three months ended December 31, 2018 and 2017, respectively, and a net (loss) gain of \$(6.1) million and \$23.3 million for the six months ended December 31, 2018 and 2017, respectively, reflected in realized and unrealized gains (losses) on interest rate swaps in the accompanying consolidated statements of operations.

Based upon the swap agreements in place as of December 31, 2018, a reduction in CHI's credit rating to BBB would obligate CHI to post additional cash collateral of \$29.0 million. If CHI's credit rating were to fall below BBB, the swap counterparties would have the option to require CHI to settle the swap liabilities at the recorded fair value, which was \$40.2 million as of December 31, 2018.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

### **8. Debt Obligations (continued)**

Following is a summary of interest rate swap contracts (in thousands):

		Swap Contracts Outstanding		Fair Value Liability (Asset)				Notional Amount		
	Maturity Date	December 31, 2018	June 30, 2018		mber 31, 2018	June 30, 2018	D	ecember 31, 2018	June 30, 2018	
Basis swaps Fixed payer swaps	3/2028 2024–2047	1 15	1 15	\$	(547) 216,010	\$ (474) 207,446	\$	30,000 1,367,840	\$ 30,000 1,373,096	
Total return swaps	2019–2020	18	19	Φ.	1,485	1,490	ф	148,857	154,462	
		34	35	\$	216,948	\$ 208,462	\$	1,546,697	\$1,557,558	

### 9. Retirement Plans

### **CHI Pension Plan**

CHI and its Direct Affiliates maintain a variety of noncontributory, defined benefit retirement plans (Retirement Plans) for their employees. Certain of these plans were frozen in previous fiscal years, and benefits earned by employees through that time period remain in the Retirement Plans, where employees continue to receive interest credits and vesting credits, if applicable. Benefits in the Retirement Plans are based on compensation, retirement age, and years of service. Substantially all of the Retirement Plans are qualified as church plans and are exempt from certain provisions of both the Employee Retirement Income Security Act of 1974 and Pension Benefit Guaranty Corporation premiums and coverage. Funding requirements are determined through consultation with independent actuaries.

CHI recognizes the funded status (that is, the difference between the fair value of plan assets and the projected benefit obligations) of its Plans in the consolidated balance sheets, with a corresponding adjustment to net assets. Actuarial gains and losses that arise and are not recognized as net periodic pension cost in the same periods are recognized as a component of changes in net assets.

Estimated amounts for the components of net periodic pension (income) expense are summarized in the table below. Amounts will be adjusted at year-end to reflect actual results, based on the final annual actuarial reports (in thousands):

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

9. Retirement Plans (continued)	Three Mon Decemb		S	Six Months Ended March 31,			
_	2018	2017	2	2018		2017	
Components of net periodic pension (incon Service cost		\$ 2.446	¢	6 076	¢	6 902	
Service cost Interest cost	3,038 46,246	\$ 3,446 41,072		6,076 92,492	\$	6,892 82,144	
Expected return on the Plans' assets	(68,989)	(70,877	)	(137,978)		(141,754)	
Actuarial losses	11,378	11,593		22,757		23,186	
<u>\$</u>	(8,327)	\$ (14,766	\$	(16,653)	\$	(29,532)	

The service cost, interest cost, expected return on the Plans' assets, actuarial losses, and amortization of prior service benefit components of net periodic pension (income) expense are recognized in the accompanying consolidated statements of operations within employee benefits expense.

### **CHI 401(k) Retirement Savings Plan**

CHI sponsors the CHI 401(k) Retirement Savings Plan (401(k) Savings Plan) for its employees whereby CHI matches 100.0% of the first 1.0% of eligible pay an employee contributes to the plan, and 50.0% of the next 5.0% of eligible pay contributed to the plan, for a maximum employer matching rate of 3.5% of eligible pay. On an annual basis and regardless of whether or not an employee participates in the 401(k) Savings Plan, CHI will also contribute 2.5% of eligible pay to an employee's 401(k) Savings Plan account. This contribution is made if an employee reaches 1,000 hours in the first year of employment or every calendar year thereafter, and is employed on the last day of the calendar year. An employee is fully vested in the plan for employer contributions after three years of service. CHI recorded 401(k) Savings Plan expense of \$57.5 million and \$53.7 million for the three months ended December 31, 2018 and 2017, respectively, and \$114.8 million and \$108.9 million for the six months ended December 31, 2018 and 2017, respectively, which is reflected in employee benefits expenses in the accompanying consolidated statements of operations.

### 10. Concentrations of Credit Risk

CHI grants credit without collateral to its patients, most of whom are insured under third-party payor agreements. CHI's exposure to credit risk on patient accounts receivable is limited by the geographical diversity of its MBOs.

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

The mix of net patient accounts receivable approximated the following:

	December 31, 2018	June 30, 2018
Medicare	27%	26%
Medicaid	11	10
Managed care	33	34
Self-pay	11	11
Commercial and other	18	19
	100%	100%

CHI maintains long-term investments with various financial institutions and investment management firms through its investment program, and its policy is designed to limit exposure to any one institution or investment. Management does not believe there are significant concentrations of credit risk at December 31, 2018 and June 30, 2018.

### 11. Commitments and Contingencies

### Litigation

During the normal course of business, CHI may become involved in litigation. Management assesses the probable outcome of unresolved litigation and records estimated settlements. After consultation with legal counsel, management believes that any such matters will be resolved without material adverse impact to the consolidated financial position or results of operations of CHI.

### 11. Commitments and Contingencies (continued)

### **Health Care Regulatory Environment**

The health care industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Management believes CHI is in compliance with all applicable laws and regulations of the Medicare and Medicaid programs. Compliance with such laws and regulations is complex and can be subject to future governmental interpretation as well as significant regulatory action, including fines,

Notes to Consolidated Interim Financial Statements (Unaudited) (continued)

penalties and exclusion from the Medicare and Medicaid programs. Certain CHI entities have been contacted by governmental agencies regarding alleged violations of Medicare practices for certain services. In the opinion of management after consultation with legal counsel, the ultimate outcome of these matters will not have a material adverse effect on CHI's consolidated financial statements.

### 12. Subsequent Events

CHI's management has evaluated events subsequent to December 31, 2018 through February 14, 2019, which is the date these consolidated financial statements were issued. There have been no material events noted during this period that would either impact the results reflected herein or CHI's results going forward, except as disclosed below.

CommonSpirit Health – Effective on February 1, 2019, CHI and Dignity Health aligned their respective ministries as a single, Catholic, not-for-profit health system known as CommonSpirit Health. CommonSpirit Health is committed to creating healthier communities, delivering exceptional patient care, and ensuring every person has access to quality health care. With its national office in Chicago, and a team of approximately 150,000 employees and 25,000 physicians and advanced practice clinicians, CommonSpirit Health operates 142 hospital and more than 700 care sites across 21 states.